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Ornithine decarboxylase (ODC) regulates the synthesis of polyamines which are 
involved in many cellular functions e.g. proliferation and differentiation. Due to its 
critical role, ODC is a tightly regulated enzyme. If the regulation fails, the activity of 
ODC increases and may even lead to malignant transformation of a cell. Increased 
ODC activity is found in many common cancers. ODC plays an important role also in 
the central nervous system (CNS). It is involved in brain morphogenesis and in the 
regulation of glutamate receptors (especially NMDA-receptors) and the K+ inward 
rectifier channels. High ODC activity and polyamine levels are considered to be  
important in the development of ischemic brain damage and they are implicated in the 
pathogenesis of Alzheimer’s disease (AD). The aim of this study was to investigate 
the molecular mechanisms by which polyamines and ODC influence cell proliferation 
and transformation (I). Furthermore, the investigations were focussed at the 
regulatory factors of the polyamine-ODC system in the CNS (II-IV). 
 
Reorganization of the actin cytoskeleton is a fundamental event during proliferation 
and cell transformation. It has been implicated that polyamines participate in the 
regulation of actin cytoskeletal dynamics, although the actual molecular mechanism 
has remained unsolved. The small G protein, RhoA is a regulator of actin 
reorganization. Some bacterial toxins are known to covalently link polyamines to 
RhoA. Polyamination activates RhoA constitutively and facilitates the intrusion of 
bacteria into cells. The present results demonstrate that polyamination of RhoA takes 
place also physiologically in cells without bacterial toxins (I). Inhibition of 
transglutaminase 2 (TG2) abolished the polyamination, thus indicating that TG2 has a 
catalytic role in the covalent linking of polyamines to RhoA. Studies on synchronized 
fibroblasts by western blotting with antibodies to RhoA showed that the 
polyamination of RhoA was most extensive in the cell cycle phases of G2 and 
mitosis. Furthermore, analysis by flow-cytometry, revealed that efficient progression 
in the cell cycle of Jurkat cells depended on the intact function of TG2 and the 
polyamination of RhoA. When cells devoid of catalytically active ODC were 
transfected with a mutant form of ODC, in which the membrane translocation PHOX-
motif was deleted, ODC activity was detected in the cytoplasmic fraction only.  
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Neither was any RhoA found in the membrane fraction of these cells whereas 
immunofluorescence staining showed a diffuse cytoplasmic distribution of RhoA. 
These results indicate that ODC not only regulates the activity of RhoA by the 
production of polyamines but also influences its intracellular distribution. 
 
A homolog of ODC was cloned from a human brain cDNA library. The novel protein 
was nevertheless devoid of ODC catalytic activity (II). It was subsequently found to 
be a novel inductor of ODC activity and polyamine synthesis, called antizyme 
inhibitor 2 (AZIN2). Transcripts of human AZIN2 were most abundant in brain and 
testis as detected by mRNA dot blot and in situ hybridization (II-IV). Ten 
alternatively spliced forms of AZIN2 were sequenced (II, IV). The distribution of the 
protein was investigated by immunohistochemistry in order to elucidate the functional 
role of AZIN2. Human brain and testis were studied more closely. Expression of 
AZIN2 was detected in steroid hormone-producing cells of the gonads: in Leydig 
cells of the testis and in luteal cells of the ovary (III). In human brain, AZIN2 was 
localized along the axons covering tracts from all areas of the CNS studied. A 
vesicular or granular distribution of AZIN2 was also detected in the somas of cortical 
pyramidal cells (IV). Reverse transcriptase PCR and western blotting revealed the 
expression of different splicing variants of AZIN2 in the white as well as grey matter 
of the brain (IV). Although the distribution of AZIN2 in pyramidal cells differed 
spatially, double immunofluorescence revealed a partial co-localization with the 
ubiquitously expressed NMDA-type glutamate receptors (NMDAR). Polyamines, 
ODC and NMDAR are implicated in the pathogenesis of AD. An accumulation of 
also AZIN2 was detected in specimens of AD brains (IV). This increased expression 
of AZIN2 was specific for AD and was not found in brains with other 
neurodegenerative diseases including CADASIL or dementia with Lewy bodies. 
 
In conclusion, the results indicate that covalent attachment of polyamines by 
transglutaminase is a physiological means of regulating the activity of RhoA. The 
translocation of RhoA to the plasma membrane, where it exerts its activity is 
dependent on the presence of catalytically active ODC. As the overactivity of ODC 
and RhoA are implicated in cell transformation, the results provide a mechanistic 
explanation of the interrelationship between the polyamine metabolism and the 
reorganization of the actin cytoskeleton occurring in cancer cells. 
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In addition, a novel regulator of polyamine synthesis, AZIN2 was cloned and 
characterized. The distribution of AZIN2 is more restricted in human tissues than its 
functional and structural homolog antizyme inhibitor 1 (AZIN1). The accumulation of 
AZIN2 in vesicle-like formations along the axons and beneath the plasma membrane 
of neurons as well as in steroid hormone producing Leydig cells and luteal cells of the 
gonads implies that AZIN2 plays a role in secretion and vesicle trafficking. 
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AZ  antizyme 
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CADASIL cerebral autosomal dominant 
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ERK extracellular-signal-regulated 
kinase 
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G1 a growth phase of the cell 
cycle 
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GAP  GTPase activating protein 
GDI guanine nucleotide-
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GEF guanine nucleotide-exchange 
factor 
GTP  guanosine triphosphate 
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triphosphate 
JunD  jun D proto-oncogene 
Kir K+ inward rectifier channel 





LIM kinase a serine kinase regulating 
cytoskeleton 
MAPK mitogen-activated protein 
kinase 
mDia mammalian diaphanous 
MDC monodansylcadaverine 
MEK kinase MAPK/ERK kinase kinase 
MLC myosin light chain 
mRNA messenger ribonucleic acid 
MYC myelocytomatosis oncogene 
NAP nuclear aggregates of 
polyamines 
NIH 3T3 immortalized mouse 
embryonic fibroblast cell line 
NMDAR N-methyl D-aspartate type 
glutamate-receptor 
ODC  ornithine decarboxylase 
ODCp ornithine decarboxylase 
paralog 
PHOX phagocyte oxydase motif 
P0  postnatal day 0 
p53  tumor protein p53 
PEST domain rich in proline, 
glutamic acid, serine, threonine  
PI3K phosphoinositide-3-kinase 
PRE polyamine response element 
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Ras  rat sarcoma oncogene 
RBL-1  rat basophil cell line 
RhoA ras homolog gene family, 
member A 
RNA  ribonucleic acid 
ROCK Rho kinase 
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rRNA ribosomal ribonucleic acid 
RT  room temperature 
siRNA small interfering RNA 
Smurf E3 ubiquitin ligase 
Src Rous sarcoma oncogene 
SSAT spermidine/spermine N1-
acetyltransferase 
TG2 transglutaminase 2 
(tissuetransglutaminase) 
TGF-β transforming growth factor β 
tRNA transfer ribonucleic acid 




Polyamines are small cationic molecules found in all eu- and prokaryotic cells. These 
molecules bind to anionic molecules such as RNA, DNA, proteins, and phospholipids. 
They induce changes in the electrostatic status leading to modifications of the 
macromolecules. Binding of polyamines typically increases the stability of a 
macromolecule by creating a more compact form and providing protection against 
endo- and exogenous hazards including irradiation and reactive oxygen species. A 
majority of the high millimolar concentration of polyamines is constantly attached to 
nucleic acids. Polyamines also function as signalling molecules especially in 
mitogenic signalling cascades. Their binding and detachment, especially to proteins, 
is rapidly regulated by e.g. transglutaminases. 
 
Figure 1. The metabolic pathway of mammalian polyamines. SAM - S-adenosylmethionine, 
adomet-DC - S-adenosylmethionine decarboxylase, SSAT - spermidine/spermine-N1 -acetyl-
transferase, PAO - polyamine oxidase. 
The metabolism of polyamines is regulated by multiple enzymes which in turn are 
tightly controlled at the transcriptional, translational and post-translational levels by 
other regulators. ODC is the first rate-limiting enzyme in polyamine synthesis and 
because of its essential role is being monitored constantly. The half-life of ODC is 
very short, only 10–20 minutes in eukaryotes, emphasizing the importance of its 
regulation. ODC is bound to its inhibitor antizyme (AZ) which targets ODC to 
proteasomal degradation independently of ubiquitination. When the concentration of 
polyamines falls, ODC is synthesized de novo and also released from the AZ-complex 
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by antizyme inhibitor. Antizyme inhibitor (AZIN) is a protein homologous to ODC 
but devoid of decarboxylating activity. Due to its homology it replaces ODC from AZ 
and leads to increased polyamine synthesis. AZ and AZIN regulate also the cellular 
uptake of polyamines. 
 
Polyamines participate in the regulation of numerous cellular functions of which 
proliferation is the most studied. Cells are unable to proliferate without polyamines. 
These are needed for the regulation of cyclins and cyclin dependent kinases (cdk), the 
reorganization of the cytoskeleton, and as a part of ras-, mitogen-activated protein 
kinase (MAPK), and src-signalling cascades. Lack of polyamines halts the cell cycle 
in G1, but also a constantly upregulated polyamine synthesis disturbs the progress of 
the cell cycle. Polyamines are considered fundamental also in differentiation and 
morphogenesis. Transgenic mice with increased activity of ODC and content of 
polyamines in the testis are infertile and show impaired spermatogenesis. Enhanced 
catabolism of spermidine and spermine in SSAT transgenic mice leads to female 
infertility with hypoplasia of the uterus and absence of the developing follicles and 
corpus luteum in the ovary. Homozygous deletion of the ODC gene (knock-out) in 
mice is embryonally lethal. The concentration of polyamines is invariably monitored 
and regulated not only by de novo synthesis and catabolism but also by active uptake 
and efflux from the extracellular space. Polyamines are obtained from alimentary 
sources and they are produced by the intestinal bacterial flora. 
 
The concentration of polyamines is elevated in several human cancers. The activity of 
ODC is constitutively increased e.g. in cancers of the prostate, breast, and colon. 
Furthermore, overexpression of ODC via transfection leads to malignant 
transformation of NIH3T3 fibroblasts indicating an oncogenic role for ODC. Such 
ODC-overexpressing cells are tumorigenic in nude mice. Polyamine analogs and 
ODC inhibitors have been studied and used as chemotherapeutics and adjuvants in the 
treatment of cancer. However, the ultimate molecular mechanisms by which 
polyamines and their regulators influence the cell transformation are not known. The 
participation of polyamines in the regulation of the cell cycle, mitogenic signalling, 




In addition to transformation and cancer, polyamines are connected to pathologies of 
the brain. Elevated ODC activity and polyamine levels are measured from brains 
affected by Alzheimer’s disease. Furthermore, in ischemic lesions polyamines 
accumulate in neurons of the penumbra. However, their role in the pathogenesis is 
still unclear. Whether polyamines are neuroprotective or neurotoxic is still 
controversial, but the assumption that they function as scavengers of free oxygen 
radicals refers to a protective role. In normal brain, polyamines participate in neuronal 
signalling. They contribute to signalling by regulating glutamate receptors including 
NMDA receptors, which are connected to memory and learning. The formation of 




REVIEW OF THE LITERATURE 
1. Functions of polyamines and ODC 
1.1. Polyamines bind nucleic acids 
 
Polyamines are small, positively charged molecules that exist in all living organisms. 
In mammals, the predominant polyamines are spermidine and spermine and their 
diamine precursor, putrescine. Due to their cationic nature in physiological pH, they 
bind cellular molecules of opposite charge: RNA, DNA, nucleotide triphosphates, 
phospholipids, and proteins (Igarashi K et al. 1982, reviewed in Bachrach U 2005). 
Only 2–15 % of polyamines are free in the cytoplasm, whereas the majority are 
bound, mainly to RNA (Igarashi K, et al. 2000). De novo synthesized polyamines are 
rapidly recruited to anionic compounds in a cell: free putrescine is estimated to vanish 
in 2h, spermidine in one day, and 60% of spermine is bound in four days 
(McCormack SA, et al. 1993). 
 
Since most of the intracellular spermidine and spermine is bound to RNA, this 
interaction is considered to mediate the majority of the functions of polyamines 
(Igarashi K et al. 2000). Polyamines bind both non-coding transfer and ribosomal 
RNAs and message RNA, consequently leading to changes in their secondary 
structure. tRNA is stabilized and protected from degradation by polyamines, whereas 
the phosphate-groups of rRNA are neutralized by spermidine and spermine, enabling 
ribosomal aggregation (Quigley GJ et al. 1978, Erdmann VA et al. 1968, Zillig W et 
al. 1959, Xaplanteri MA et al. 2005, Venkiteswaran S et al. 2005). Polyamine-
mediated changes usually stabilize the structures and stimulate the efficacy and 
fidelity of translation (Igarashi K et al. 1974, Igarashi K et al. 1979, Jelenc PC et al. 
1979). Due to its higher charge compared to spermidine or putrescine, spermine 
stabilizes and aggregates anionic molecules more potently. 
 
In prokaryotic cells, translational frameshifting in mRNA reading is a common 
regulative mechanism. Frameshifting in eukaryotes, on the other hand, is a rare found 
only in the translation of antizyme that is expressed also in mammals and in the Ty1 
transposable element in yeast. Antizyme (AZ) is a negative regulator of ODC activity 
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and polyamine transport. Its translation is reinforced by elevation in polyamine 
concentration. Polyamines induce +1 shift of the reading frame in ribosomes leading 
to the formation of active, full-length antizyme-protein, which further decreases the 
concentration of polyamines (Matsufuji S et al. 1995). mRNA of AZ contains 5´-
element that senses the concentration of polyamines. During translation in ribosomes, 
polyamines might also slow down the reading facilitating frame-shifting (Petros LM, 
et al. 2005). Thus, polyamines display negative feedback regulation via antizyme. The 
archaic regulation of expression by ribosomal frame-shifting underscores the 
fundamental nature of the polyamine metabolism. 
 
Elevated levels of polyamines stimulate the expression of certain transcription factors 
related to the mitogen-activated protein kinase (MAPK) pathway and activated by 
mitogenic stimulus (c-fos, c-myc) (Patel AR et al. 1997). Instead, depletion of 
polyamines provided by the administration of the ODC inhibitor, DFMO (α-
difluoromethylornithine) decreases the mRNA levels of c-fos, c-myc, c-jun, and Egr-1 
(Wang JY et al. 1993, Li L et al. 2001, Stephenson AH et al. 2004). Polyamine 
depletion halts progression of the cell cycle. Decreased levels of polyamines also 
stabilize the transcripts of certain growth inhibitory genes, e.g. p53, TGF-β, and junD 
(Patel AR et al. 1997, Li L et al. 2002, Li L et al. 1999). The mechanism by which 
polyamines regulate the expression of various genes is not fully established, but the 
polyamine response element (PRE) has been recognized in the untranslated region of 
certain genes, e.g. spermidine-spermine-N1-acetyltransferase (SSAT) (Wang Y et al. 
1998, Stephenson AH et al. 2006).  SSAT regulates the levels of polyamines by 
converting spermine to spermidine and spermidine to putrescine, and thereby 
contributes to the catabolism and circulation of polyamines. 
 
Polyamines bind to phosphate groups of double-stranded and even triplex and 
quadruplex DNA, forming intra- and interchain bridges which stabilize the structure 
(Raspaud E et al. 1998, Saminathan M et al. 1999). Furthermore, polyamines regulate 
the conformational changes of DNA between A, B, and Z forms (Bryson K et al. 
2000, Hasan R et al. 1995). Nuclear aggregates of polyamines (NAP) are concentrates 
of phosphate anions and polyamines which bind DNA and further stabilize it, but also 
enable the duplication of DNA during proliferation. The packing of DNA is 
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reinforced by polyamines in nucleosomes which stabilizes the structure and protects it 
from damage induced by e.g. radiation, reactive oxygen species, or enzymatic 
digestion (Snyder RD 1989a, Khan AU et al. 1992, Pedreno E et al. 2005, Snyder RD 
1989b). Depletion of polyamines, instead, prolongs the cell cycle causes 
chromosomal aberrations, e.g. chromosome elongation, unpacking, fragmentation, 
and breaks. Polyamines regulate histone-modifying protein complexes leading to 
changes in the acetylation of histones (Hobbs CA et al. 2002). Acetylation of histones 
enables the binding of promoting factors, e.g. transcription factors, to selected genes. 
Furthermore, the binding of polyamines to DNA provokes its bending, which is of 
importance in the initiation of transcription (Peng HF, et al. 2000). DNA bending 
enables the binding of RNA polymerases and transcription factors thus promoting 
gene expression. 
 
The binding of polyamines to nucleic acids serves a dual function: 1) the structure of 
DNA and RNA is stabilized through packing and protected from degradation; 2) 
polyamines respond to mitogenic stimuli by enhancing proliferation. This latter task 
requires a higher concentration of free, rapidly mobilized polyamines whereas in 
nucleic acid stabilization the binding is more stabile. Since depletion as well as excess 
of polyamines can have a similar effect on cell behaviour, e.g. the inhibition of 
proliferation and the induction of apoptosis, polyamines have been suggested to 
dynamically regulate the proliferative state of a cell (for a review, see Thomas T et al. 
2001). Electrostatic forces between cationic polyamines and anionic nucleic acids are 
believed to be responsible for the interactions. However, structural aspects, such as 
the flexibility and rod-like structure of polyamines and the sequence-specificity of 
nucleic acids also play a role in the binding. 
 
1.2. Interaction of polyamines with proteins 
 
Transglutaminases (TG) are widely distributed bifunctional enzymes, which also have 
non-catalytic functions (for reviews, see Griffin M et al. 2002, Lorand L et al. 2003). 
These enzymes catalyze the hydrolyzation of GTP and post-translational modification 
of proteins, the reactions of which are competitive and partly reversible. TGs induce 
transamidation of amine compounds to γ-glutaminyl residues of proteins. Polyamines 
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are the major source of amines (Piacentini M et al. 1988, Folk JE et al. 1980), but also 
other primary amines are utilized in the covalent linkages (Guilluy C et al. 2007). 
Incorporation of amines increases the net charge of a protein, which changes 
conformation, solubility, stability, and interactions with other macromolecules. 
Transamidation of proteins is considered a biologically important post-translational 
modification. TG also catalyzes protein-protein cross-linking which triggers many 
physiological reactions of polymerization and aggregation, e.g. the clotting of blood 
and semen. Increased transglutaminase activity has been detected in many diseases, 
including Alzheimer’s disease and Huntington disease (Tucholski J et al. 1999, Jeitner 
TM et al. 2008, Muma NA 2007). Post-translational modifications catalyzed by TGs, 
including transamidation, esterification, and hydrolysis require high concentration of 
Ca2+. This can be achieved only in pathological states in which the intracellular Ca2+-
storages are released, or by an influx of extracellular Ca2+ (Smethurst PA et al. 1996). 
In addition, transglutaminases have functions which are unrelated to their Ca2+-
dependent enzymatic reactions: they modify the extracellular matrix and cellular 
structures via interactions with the cytoskeleton, adhesions, and integrins; they also 
participate in signal transduction (Janiak A et al. 2006, Mian S et al. 1995, Gentile V 
et al. 1992). 
 
TG2 (tissueTG) is a ubiquitously expressed isoform localized in the cytoplasm but 
found also in the plasma membrane and nucleus (Lesort M et al. 1998, Slife CW et al. 
1985). TG2 has been found to link polyamines to (i.e. polyaminate) the G protein, 
RhoA at its glutamine 63. This polyamination prevents the GTPase activity of RhoA, 
sustaining it in a constitutively active, GTP-bound form (Flatau G et al. 1997). 
Certain bacterial toxins function as transglutaminases and activate RhoA by 
polyamination.  Since RhoA is a regulator of the actin cytoskeleton, this provokes the 
formation of stress fibers and focal adhesions (Masuda M et al. 2000). Polyamination 
of RhoA has also been implicated in neurite outgrowth and neuronal differentiation 
(Singh US et al. 2003). The migration of epithelial cells during intestinal restitution 
has also been demonstrated to be dependent on the concentrations of polyamines and 
Ca2+ and the activity of Rho proteins (Rao JN et al. 2001, Ray RM et al. 2003). 
  
A specific example of polyamine-dependent protein modification is the incorporation 
of hypusine to eukaryotic initiation factor 5A (eIF5A). A 4-aminobutyl moiety of 
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spermidine is transferred to eIF5A and further modified to hypusine (Cooper HL et al. 
1983). The function of eIF5A is dependent on hypusinylation, and the lack of 
spermidine inhibits hypusinylation and arrests cell growth (Schnier J et al. 1991, Park 
MH, et al. 1993). The role of hypusine in cell proliferation is emphasized by the 
finding that the generation of hypusine is significantly elevated in NIH 3T3 cells 
transformed by the ras oncogene (Chen ZP et al. 1997). Initially, eIF5A was 
considered to be an initiator of transcription, but later it was found to play a role in the 
regulation of mRNA degradation (Zuk D et al. 1998). 
 
The regulation of ion channels by polyamines is of physiological importance in 
protein-polyamine interaction. Small, cationic polyamines existing both intra- and 
extracellularly gate strong K+ inward rectifier channels (Kir) and α-amino-3-hydroxy-
4-methyl-5-isoxazolepropionic acid- (AMPA), kainate-, and N-methyl-D-aspartate 
(NMDA)-type glutamate channels. Polyamines permeate into the channel pore and 
block the flow of ions through the Kir channels depending on the voltage. In the 
glutamate receptors, the attachment of polyamines to specific binding sites modulates 
the electrostatic environment and thus influences the binding capacity of the ligands 
(reviewed in Williams K 1997). Kir channels allow the inward flow of K+ under a 
negative membrane potential (Nichols CG et al. 1997). When depolarization abolishes 
the voltage difference, spermine and spermidine block the channel causing a relative 
decrease in intracellular [K+], which in turn potentiates the amplitude of the action 
potential (Lopatin AN et al. 1994, Fakler B et al. 1994). Small depolarization waves 
do not induce the block, but an inflow of K+ rather continues and counteracts the 
initiation of depolarization. Kir-channels thus set the threshold for the action potential 
and stabilize the membrane. They also amplify the depolarization signals that are 
strong enough to provoke action potentials. Depletion of spermine/spermidine after 
the inhibition of S-adenosylmethionine decarboxylase or ODC reduces the inward 
rectification in RBL-1 and CHO cells, respectively (Bianchi L et al. 1996, Shyng SL 
et al. 1996). A similar reduction in inward rectification was observed in a Gyro-mouse 
with deleted spermine synthase gene and thus lacking spermine (Lopatin AN et al. 
2000). In cardiac myocytes, the excitability is reduced after a decrease in polyamine 
concentration, suggesting that it might serve as a potential target in the treatment of 
arrhythmia (Nichols CG, et al. 1996). Kir channels function in various cells, but the 
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subtypes of channels that are regulated by polyamines reside predominantly in the 
brain, heart, and skeletal muscle (Oliver D et al. 2000). 
 
The NMDA-, AMPA-, and kainate receptors respond to a presynaptic release of 
neurotransmitters by creating excitatory postsynaptic potentials (epsps) and 
depolarization. NMDA-type glutamate receptors allow the intracellular flow of Na+ 
and Ca2+ upon ligand, i.e. glutamate and glycine, binding (McBain CJ et al. 1994).  
The extracellular portion of the receptor contains at least two polyamine-binding sites 
in addition to a binding site in the channel pore to which polyamines have access from 
both intra- and extracellular sides. The binding of spermine and spermidine to the 
receptor enhances the binding of the co-ligand, glycine, and increases the probability 
of the channel to open independently of glycine (Ransom RW et al. 1990). This leads 
to potentiation of the signalling (Benveniste M et al. 1993). Quite the contrary, 
polyamines can inhibit the flow of ions by blocking the channel pore (Araneda RC et 
al. 1999). They also decrease the affinity of glutamate to its receptor (Williams K et 
al. 1994). Physiologically the most relevant mechanisms of action are considered to 
be the glycine-independent activation of channel opening and the attenuation of the 
glutamate-affinity (Williams K 1997). Thus, polyamines strengthen the NMDA 
response to activation signalling by affecting the amplitude and by decreasing the 
length of the response. This kind of vigorous, but rapidly silenced signalling is 
considered fundamental in long-term potentiation and depression, which are pivotal 
for memory and learning (MacDonald JF et al. 2007, Grosshans DR et al. 2002). 
Different subtypes of this receptor vary in their ability to bind polyamines, and also in 
their response to polyamine binding (Williams K et al. 1994, Durand GM et al. 1993). 
Neuronal stimulation alters the composition of receptors and new receptors are 
recruited to the synaptic density from mobile transport packets and extrasynaptic 
membrane areas (Lau CG et al. 2007, Quinlan EM et al. 1999, Ying Z et al. 1998, 
Washbourne P et al. 2004).  Subunits of receptors with a high affinity for spermine 
are expressed embryonally and neonatally, indicating a role for polyamines in 
morphogenesis, e.g. synaptogenesis and axonogenesis (Zhong J et al. 1995). 
 
AMPA- and kainate-type glutamate receptors mediate fast synaptic transmission at 
excitatory synapses by permeating Na+ and occasionally also Ca2+. Subtypes passing 
Ca2+ are voltage-dependently blocked by polyamines, establishing inward 
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rectification. Such receptors are expressed in the fetal and neonatal central nervous 
system (Shin J et al. 2005, Koh DS et al. 1995, Bernard A et al. 1994). Similarly to 
the NMDA receptors, the regulation of perinatal kainate receptors by polyamines 
contributes to synapse formation and plasticity.  
 
1.3. Polyamines and the cell cycle/ cell proliferation 
 
The induction of proliferation has been considered one of the most important function 
of polyamines and the enzymes responsible for their synthesis, i.e. ornithine 
decarboxylase (ODC) and S-adenosylmethionine decarboxylase (adomet-DC). The 
concentration of free polyamines is low in non-proliferating cells, but a significant 
rise in polyamine levels is noted in cells entering the proliferation cycle. The amount 
of polyamines and the activities of polyamine-synthesizing enzymes increase rapidly 
in late G1 and in the transition of G2 to mitosis (Fredlund JO et al. 1995). In the S-
phase and mitosis, polyamine catabolism by spermidine/spermine N1-
acetyltransferase (SSAT) overdrives the synthesis rate (Bettuzzi S et al. 1999).  The 
increase as well as the following decrease in polyamine concentration are necessary 
for the proliferation cycle to progress accurately. The fluctuations of polyamines 
during the proliferation cycle are associated to sequential activation of cyclins and 
cyclin dependent kinases, especially cyclinE/cdk2 and cyclin A/cdk2 complexes 
(Gilmour SK, et al. 1999). One of the early signals in mitogenesis is the stimulation of 
ras, which further activates the mitogen-activated protein kinase (MAPK) and 
phosphoinositide-3-kinase (PI3K) pathways (reviewed in McCubrey JA et al. 2007). 
MAPK and PI3K signalling stimulate the transcription and the activation of ODC 
(Wei LH et al. 2008, Origanti S et al. 2007, Shantz LM 2004, Flamigni F et al. 1997) 
via the transcription factor c-myc that binds to specific responsive elements in the 
promoter of ODC (Bello-Fernandez C et al. 1993). The resulting increases in ODC 
activity and polyamine concentration enhance the growth stimulus by reinforcing the 
expression of transcription factors, including c-myc, c-fos, and c-jun, creating a loop 
of positive feedback. Inhibition of ODC activity by DFMO leads to polyamine 
depletion and cell cycle block in G1/G0 by imbalancing the expression of the above-
mentioned transcription factors and cell cycle inhibitors p21Waf1/Cip1, p27Kip1, p53, 
junD/AP-1, and TGF-β (Wang JY et al. 1993, Ray RM et al. 1999, Ravanko K et al. 
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2000, Patel AR et al. 1999, Patel AR et al. 1998). The fluctuation of polyamines 
during the proliferation cycle is associated with sequential activation of cyclins and 
cyclin-dependent kinases, especially cyclinE/cdk2 and cyclin A/cdk2 complexes 
(Gilmour SK et al. 1999).  
 
1.4. In reproductive organs 
 
ODC is highly expressed in the human reproductive organs, i.e. testis, ovary, and 
prostate. Polyamines were originally described in the semen, where they are secreted 
from the prostate. ODC and polyamines are required for spermatogenesis and 
proliferation of the germinal epithelium in murine testicular tissue (Alcivar AA et al. 
1989, Qian ZU et al. 1985, Weiner KX et al. 1992). Transgenic mice overexpressing 
ODC developed infertility, with reduced size of testes and impaired spermatogenesis 
due to excessive amounts of putrescine (Halmekytö M et al. 1991, Hakovirta H et al. 
1993). Ivanov et al. and Tosaka et al. (Ivanov IP et al. 2000, Tosaka Y et al. 2000) 
originally identified and cloned a testis-specific antizyme (AZ3 or OAZ-t) which is 
expressed exclusively in haploid germ cells, pointing to the need to tightly control the 
activity of ODC and of polyamines. 
 
ODC has also regulatory functions in the gonads, unrelated to proliferation. 
Testosterone-producing Leydig cells of mature murine testis display a high ODC 
activity – even higher than that found in proliferating spermatogenic cells (Qian ZU et 
al. 1985). In Leydig and Sertoli cells, the activity of ODC is regulated by AZ1 
(Tosaka Y et al. 2000). In steroid-hormone-producing cells of testis and ovary, the 
activity of ODC is stimulated by luteinizing hormone (LH) (Osterman J et al. 1983, 
Maudsley DV et al. 1974, Levine JH et al. 1973). Treatment with DFMO reduces the 
production of progesterone by inhibiting LH-induced preovulatory rise in ODC 
activity in mouse corpus luteum (Bastida CM et al. 2002). Intact ODC activity is also 
needed for normal folliculogenesis and luteinization in mouse ovary (Bastida CM et 
al. 2005). The gonadotropin-induced activation of ODC in the gonads suggests that 
ODC has a role in the regulation of steroid hormone synthesis or secretion. 
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2. Regulation of ODC 
 2.1. Antizymes 
 
Antizymes (AZ) are proteins which sequester monomeric ODC molecules. AZs 
prevent the dimerization and formation of enzymatically active ODC  (Heller JS et al. 
1976, Murakami Y et al. 1994). Binding of AZ leads to conformational changes in 
ODC and exposure of the C-terminal PEST sequence (Li X et al. 1993) that provokes 
translocation to the 26S proteasome for degradation without ubiquitination  
(Murakami Y et al. 1992). AZ itself is not degraded together with ODC, but is 
recycled back to the cytoplasm. Due to antizyme-induced degradation, the half-life of 
ODC, only 10–20 min, is among the shortest known for proteins in mammalian cells  
(Murakami Y et al. 1985). A significant amount of ODC is in complex with AZ in 
mouse brain. ODC can be released and activated from this complex which might thus 
serve as a reservoir of rapidly activated enzyme  (Laitinen PH et al. 1986).  
 
Three isoforms of AZ have been recognized: AZ1 and 2 are distributed ubiquitously. 
The expression of AZ3, instead, is restricted to post-meiotic testicular germ cells  
(Ivanov IP et al. 2000, Tosaka Y et al. 2000) in which it is assumed to prevent the 
accumulation of cytotoxic amounts of polyamines. The recent results suggest a role 
for AZ3 also in the formation of head and tail connection in sperm (Tokuhiro K, et al. 
2009). All three antizymes induce inhibition and degradation of ODC, although the 
expression level of AZ2 is lower  (Ivanov IP et al. 1998, Zhu C et al. 1999, Snapir Z 
et al. 2008b).  AZ1 and 2 also interact with yet unrecognized polyamine transporters 
and block the uptake of polyamines when the intracellular concentration is increasing  
(Suzuki T et al. 1994, Mitchell JL et al. 1994).  
 
An increased polyamine content protects AZ from ubiquitin-mediated degradation 
and enhances AZ expression by affecting the rate of ribosomal frame-shifting  
(Matsufuji S et al. 1995, Palanimurugan R et al. 2004). AZ1 contains also a 
mitochondrial targeting motif. It is transported to the mitochondrial membrane where 
it depolarizes the membrane and activates the caspase cascade leading to the 
induction of apoptosis  (Gandre S et al. 2003, Liu GY et al. 2006).  
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Over-expression of AZ1 inhibits cell proliferation and growth via ODC inhibition and 
reduction of the polyamine content  (Murakami Y et al. 1994). Furthermore, in 
prostate cancer cells, failure of AZ induction is related to unregulated proliferation  
(Koike C et al. 1999). Expression of AZ in transgenic mouse reduced tumorigenesis 
in the skin  (Feith DJ et al. 2001). Thus, AZ can be considered a tumor suppressor. 
Depletion of AZ in cultured cells leads to over-duplication of centrosomes, whereas 
the silencing of antizyme inhibitor (AZIN) reduces centrosome abnormalities  
(Mangold U et al. 2007). These data suggest that AZ and AZIN are connected to the 
early stages of carcinogenesis in which the loss of tumor suppressors triggers defects 
in centrosome functioning. 
 
Recent data suggest that antizyme is not solely a regulator of ODC but also controls 
the degradation of other proteins that participate in growth regulation, e.g. cyclin D1, 
Smad1, and Aurora-A  (Newman RM et al. 2004, Fong LY et al. 2003, Gruendler C et 
al. 2001, Lim SK et al. 2007) 
 
 
Figure 2. The interplay of antizyme (AZ), antizyme inhibitor (AZIN), and ornithine 
decarboxylase (ODC) in the regulation of polyamine concentration. ODC catalyzes 
the synthesis of putrescine which is a precursor for higher polyamines, spermidine 
and spermine. AZ inhibits the activity of ODC and blocks the uptake of polyamines 
when the concentration of polyamines increases. AZIN counteracts AZ which leads to 




2.2. Antizyme inhibitors 
 
Antizyme inhibitors (AZIN) have arisen from ODC by gene duplication (Kidron H, et 
al. 2007) and thus share a high degree of sequence similarity with ODC  (Murakami 
Y et al. 1996). Due to the homology, AZINs bind AZs, with even higher affinity than 
ODC, and thus liberate ODC from the heterodimer complex with AZ resulting in the 
formation of active homodimers and increased ODC activity (Mangold U et al. 2004, 
Fujita K et al. 1982). The binding of AZIN to AZ blocks also the inhibition of 
polyamine transporters mediated by AZ, and the uptake of polyamines is enhanced  
(Keren-Paz A et al. 2006, Snapir Z et al. 2008a). The binding of AZ to AZIN or ODC 
is reversible, and the equilibrium is constantly monitored and adjusted by the 
concentration of polyamines. Even though AZ promotes ODC for degradation, it 
actually protects AZIN from ubiquitination and targeting to proteasomes  (Bercovich 
Z et al. 2004).  In biochemical assays, AZIN binds all known AZs, AZ1-3  (Mangold 
U et al. 2004). AZIN remains a monomer under physiological conditions and it is 
unable to bind the cofactor, pyridoxal-L-phosphate, which is needed for the enzymatic 
activity of ODC  (Albeck S et al. 2008).  
 
AZIN increases the concentration of polyamines and has been demonstrated to 
promote proliferation and even transformation, whereas siRNA mediated down-
regulation of AZIN expression reduces proliferation  (Keren-Paz A et al. 2006, Kim 
SW et al. 2006, Choi KS et al. 2005). RNA interference of AZIN causes also the 
accumulation of multinucleated cells  (Murakami Y et al. 2009). Interestingly, the 
same phenomenon was detected in cells in which the expression of ODC was 
constitutively targeted to the membrane  (Heiskala M et al. 1999). In addition, the 
transcription of AZIN is increased by growth stimuli, prior to induction of ODC  
(Nilsson J et al. 2000). During the cell cycle, AZIN is activated similarly to ODC in 
late G1 and again in G2/M, and during mitosis (M) it is located in the centrosome 
analogously to AZ  (Murakami Y et al. 2009). The growth-promoting activity of 
AZIN may not be solely dependent on the neutralization of AZ, since AZIN has been 
demonstrated to stabilize cyclin D1 independently of the AZ-binding (Kim SW et al. 
2006). By using the gene-trap technique, a mouse line with a disrupted AZIN was 
generated  (Tang H et al. 2009). The deletion turned out to be lethal at P0 and these 
mice had diminished levels of ODC activity, putrescine, and spermidine indicating 
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their importance for AZIN in embryogenesis. This experiment also demonstrated the 
in vivo functional role of AZIN in polyamine regulation. The expression of AZIN1 is 
elevated in human gastric cancer compared to normal gastric tissue  (Jung MH et al. 
2000) as well as in ras-transformed fibroblasts  (Keren-Paz A et al. 2006). AZIN also 
promotes the survival of various types of cancer cells via activation of ODC under 
hypoxic conditions  (Svensson KJ et al. 2008). In carcinogenesis, activation of ODC 
is considered to be an early step in malignant transformation. It has, however, been 
postulated that the activation of ODC might actually proceed via induction by AZIN 
(Keren-Paz A et al. 2006). ODC activation itself leads to a rapid increase in the 
amount of AZ, leading to the reciprocal diminution of ODC activity and polyamine 
uptake. In contrast, the activation of AZIN blocks AZ and promotes cell growth via 
sustained polyamine accumulation.  
 
 2.3. Spatial regulation of ODC 
 
Intracellular compartmentalization of polyamines is functionally of great importance, 
since polyamines participate simultaneously in various cellular functions in the 
nucleus, mitochondria, plasma membrane, secretory vesicles, and cytoplasm. 
Investigations on the localization of ODC have proven difficult due to its extremely 
short half-life, and thus minute amounst of detectable protein. On the other hand, 
problems have been encountered in determining the compartmentalization of 
polyamines with the larger pool of bound polyamines compared to freely recruitable 
ones. 
 
Polyamines take part in the modulation of various cellular signalling cascades for 
which they are either synthesized de novo or transported from extracellular spaces. 
Polyamines bound to nucleic acids and proteins are considered rather inactive in the 
event of the rapid recruitment for signalling (Watanabe S et al. 1991). Mitogenic 
signalling translocates ODC to the nucleus  (Schipper RG et al. 2004, Schipper RG et 
al. 1999), possibly in connection with antizyme that is considered to regulate the 
nucleocytoplasmic shuttling of ODC. Indeed, AZ contains two nuclear export signals  
(Murai N et al. 2003). Immunochemical stainings from different cell lines indicate 
that AZ is mainly localized to the nucleus in actively proliferating cells, whereas in rat 
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brain it is also found in the cytoplasm  (Mangold U et al. 2007, Schipper RG et al. 
2004, Kilpelainen P et al. 2000). However, the nuclear transport of AZ is deemed 
important during the development of the rat central nervous system  (Gritli-Linde A et 
al. 2001). Epitope-tagged AZIN1 has also been detected in the nucleus of 
proliferating, cultured cells  (Lopez-Contreras AJ et al. 2009) suggesting that 
reciprocal activities of AZ and AZIN1 mediate the fluctuations in ODC activity 
during the cell cycle. However, the role of ODC in the synthesis of nuclear 
polyamines needs to be investigated further, since the presence of other enzymes 
needed for polyamine synthesis have not been described for the nucleus. If the 
function of nuclear proteasomes is restricted, ODC accumulates in the nucleus, 
indicating that ODC degradation targeted by AZ occurs also in the nucleus  (Gritli-
Linde A et al. 2001). AZ might have a more potent role in the degradational targeting 
in the nucleus, since AZ mediates also the degradation of the oncogene Aurora-A, the 
function of which is related to the progression  of mitosis  (Lim SK et al. 2007). 
During transition from prophase to telophase in mitosis, the proportions of AZ and 
AZIN1 are located in the centrosomes where they facilitate the completion of mitosis 
(Murakami Y et al. 2009). Overactivity of AZ leads to a decrease in the number of 
centrosomes, whereas the increased activity of AZIN1 is followed by an accumulation 
of excess centrioles (Mangold U et al. 2007).  After mitosis, the entire orchestra of 
polyamine regulators, ODC, AZ1, AZIN1, and AZIN2, is detected in the perinuclear 
space  (Mangold U et al. 2007, Schipper RG et al. 2004, our unpublished data). In 
addition to the centrosomes, which are located perinuclearly, ODC has been identified 
in the rough endoplasmic reticulum of human neurons  (Bernstein HG et al. 1999). 
Perinuclearly, phosphorylated ODC colocalizes also with the keratin meshwork, the 
disruption of which is accompanied by a diffuse cytoplasmic spread of ODC  
(Pomidor MM et al. 1999). Specific phosphorylation of serine 167 in the p47PHOX-like 
membrane-translocation motif relocates ODC to the plasma membrane upon cell 
activation  (Heiskala M et al. 1999).  
 
The induction of apoptosis is accompanied by an increase in ODC activity, and the 
resulting accumulation of putrescine is assumed to contribute to the activation of 
apoptotic signalling cascades. However, polyamines have also been proposed to play 
an antiapoptotic role (for a review, see Schipper RG et al. 2000). Conversely, the 
inhibition of ODC by DFMO and the depletion of polyamines protect cells from 
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apoptosis initiated by both extrinsic (receptor-induced) and intrinsic (mitochondria-
derived) pathways  (Ray RM et al. 2000). Although ODC itself has not been detected 
in mitochondria, AZ1 contains an N-terminal motif for mitochondrial targeting  
(Gandre S et al. 2003). An overexpression of AZ1 in hematopoietic cells leads to its 
accumulation in mitochondria, which is subsequently followed by caspase cascade- 
and cytochrome c-mediated apoptosis  (Liu GY et al. 2006). Apoptosis, in which 
partly overlapping signalling cascades with growth induction are activated, 
exemplifies the necessity of compartmentalization and localized regulation of 
polyamines and the regulators of their synthesis. 
 
In order to function as neuromodulators in neuronal ion channels, the concentration of 
polyamines needs to be regulated rapidly: both the uptake and release of polyamines 
needs to be controlled upon signalling. Neocortical rat glia cells are capable of 
efficiently transporting polyamines from the extracellular space and storing them 
intracellularly. Polyamines are also recruited to synaptic vesicles and synaptosomes in 
neurons  (Masuko T et al. 2003). Conversely, spermine is released from hippocampal 
slices to the extracellular space upon depolarization. Polyamine transporters, still 
uncharacterized at the molecular level, are found in most cell types. These 
transporters accept a wide range of structural analogs of polyamines, and the net 
influx through them is enhanced by the depletion of polyamines  (Cullis PM et al. 
1999). Instead, if the intracellular concentration of polyamines is increasing, the 
transporters are inhibited by AZ  (Suzuki T et al. 1994, Mitchell JL et al. 1994). Cells 
contain vast amounts of polyamine-sequestering vesicles (PSV) into which the 
uptaken polyamines are believed to be accommodated by H+:polyamine carriers   
(Cullis PM et al. 1999, Soulet D et al. 2004). Free polyamines apparently do not float 
in the cytoplasm, but are rather stored in vesicles so as to be rapidly released upon 
stimulus. It has been postulated that PSVs may serve as a major reservoir of 
polyamines, a mechanism which prevents the cytotoxic effects of free polyamines and 
provides a readily available tool for signalling purposes  (Poulin R et al. 2006). In 
accordance with this model, the application of NMDA in order to activate its receptor 
has been demonstrated to induce rapid release of spermidine and spermine to the 
extracellular space (Fage D et al. 1992). In addition to their regulators, polyamines 
have also been described to relocate intracellularly upon signalling. Proliferating and 
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migrating cells of the retinal pigment epithelium recruit polyamines from membrane 
patches to cytoplasmic granules  (Johnson DA et al. 2002).  
 
3. The actin cytoskeleton 
3.1. The regulation and functions of Rho 
 
A cell is a three-dimensional structure in a three-dimensional environment. It is part 
of a larger complex of other cells, and its viability and functions are mainly 
determined by the changes in its near surroundings. When the environment creates 
tension to the cell boundaries leading to changes in the cell shape or adhesions to the 
environment, signal cascades are activated inside the cell leading to appropriate 
actions to respond to these changes. Important mediators between mechanical 
rearrangements and chemical cascades are cytoskeleton inside the cell and adhesion 
points to the surrounding cells and extracellular matrix in the plasma membrane{{51 
Ingber,D. 1999; }}. Small G-proteins, Rhos, play an essential role in the regulation of 
both adhesions and cytoskeletal rearrangements {{47 Ridley,A.J. 1992; }}. Rho 
(referring to RhoA, B, and C) belongs to a family of Rho GTPases comprised of 26 
known members of which the most studied are RhoA, Rac1, and Cdc42, and to a 
larger superfamily of ras-proteins  (Takai Y et al. 2001). Numerous members of the 
Rho family proteins participate in various cellular processes including proliferation, 
migration, cell polarity, and vesicle trafficking (Jaffe AB et al. 2005). Rho functions 
as a main regulator of actin polymerization. Activation of Rho in cultured cells leads 
to the formation of actin stress fibers and focal adhesions (Ridley AJ et al. 1992). Rho 
is active in its GTP-bound form, whereas hydrolysis of GTP to GDP renders it 
inactive and unable to interact with its downstream effectors. The activity of Rho is 
regulated by various proteins belonging to three groups (Rossman KL et al. 2005, 
Kaibuchi K et al. 1999). The GTPase-activating proteins (GAP) catalyze the intrinsic 
hydrolysis of GTP to GDP, leading to inactivation of the Rho proteins. The guanine 
nucleotide-exchange factors (GEF) activate Rho proteins by stimulating the change of 
GDP to GTP. GEFs selectively recruit proteins of the Rho family to the site of action 
where they form multimolecular complexes with appropriate downstream effectors. 
Nearly 70 different GEFs have been described with pleiotropic functions in the 
pathogenesis of cancer, invasion of microbes, and development (Rossman KL et al. 
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2005). The guanine nucleotide-dissociation inhibitors (GDI) bind GDP-Rho and keep 
it in an inactive form in the cytoplasm. Rho GAPs, GEFs, and GDIs regulate the 
activity and localization of Rho, and the availability of selective effectors. 
 
The Rho proteins are post-translationally modified by attachment of an isoprenyl 
group to the CAAX box in the C terminus (Hori Y et al. 1991). The isoprenyl group 
targets the protein to specific subcellular membranes (Hori Y et al. 1991). In the case 
of RhoA, the geranyl-geranyl tail attaches it to phospholipids in the plasma 
membrane. GDI-binding to Rho-GDP induces a change of conformation in such a 
way that the isoprenyl tail of Rho is hidden (DerMardirossian C et al. 2005). This 
prevents the membrane translocation of Rho and its interactions with downstream 
effectors. Rho can also be post-translationally phosphorylated. Several bacterial 
toxins modify Rho by ADP ribosylation, glycosylation and transamidation. 
Transamidation, consisting of deamidation and polyamination, is catalyzed by 
bacterial cytotoxic necrotizing factors with transglutaminase activity (Schmidt G et al. 
2001). This leads to constitutive activation of Rho by preventing the hydrolysis of 
GTP (Masuda M et al. 2000). Mammalian transglutaminases also transamidate Rho, 
although its functional significance is still unknown (Flatau G et al. 1997). 
 
Actin nucleators, protein kinases, and phospholipases are downstream targets of the 
Rho family proteins. Rho itself interacts with and regulates many functionally diverse 
downstream effectors which initiate a network of signalling cascades involved in 
transcription and cytoskeletal reorganization  (Bustelo XR et al. 2007). Rho GEFs 
tether the effectors to the plasma membrane where Rho is located and directs 
downstream signalling (Buchsbaum RJ 2007). The interaction of Rho with effectors 
induces conformational change in downstream targets; this is often needed for their 
activation and assembly to hot spots (Bishop AL et al. 2000). The main effectors of 
Rho are ROCK (Rho-associated coiled-coil kinase) and mDia (mammalian homolog 
of Drosophila diaphanous). ROCK is a serine/threonine kinase that induces 
phosphorylation of the myosin light chain (MLC) phosphatase. This induces cross-
linking of myosin II to actin and leads to the formation of contractile actomyosin 
filaments  (Riento K et al. 2003). ROCK inactivates actin severing cofilin and 
stabilizes actin filaments  via phosphorylation of the LIM kinase (Ohashi K et al. 
2000). Rho induces polymerization of actin and the formation of actin fibers through 
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diaphanous-related formin, mDia (Li F et al. 2003). ROCK and mDia modulate the 
activities of each other, and their balance determines the type of stress fibers and the 
shape of a cell (Watanabe N et al. 1999, Tsuji T et al. 2002). Another effector, the 
citron kinase, regulates also the phosphorylation of MLC, but this interaction takes 
place in the cleavage furrow during cytokinesis (Madaule P et al. 1998). ROCK 
activity regulates microtubule collapse and the stabilization of different target proteins  
(Arimura N et al. 2000, Palazzo AF et al. 2001). By regulating the serum response 
factor and interacting with MEKK1, Rho promotes the transcription of genes 
encoding cytoskeletal components. Rho also contributes to the transcription of many 
growth-related genes (Miralles F et al. 2003, Gallagher ED et al. 2004). 
 
The inhibition of Rho family proteins blocks the cell cycle at G1 (Olson MF et al. 
1995). The influence of Rho on this block is regarded to result from the regulation of 
cyclin D1 and the cdk inhibitors, p21cip1 and p27kip1  (Welsh CF et al. 2001, Olson MF 
et al. 1998, Weber JD et al. 1997). The Rho target ROCK is involved in this 
regulation (Roovers K et al. 2003). Perhaps an even more important role for Rho in 
the regulation of the cell cycle takes place during mitosis. Mediated by ROCK and 
myosin II, Rho is needed for the correct positioning of centrosomes during prophase 
(Rosenblatt J et al. 2004). During cytokinesis, Rho also contributes to the formation 
and functioning of the contractile ring and to the localization of the cleavage furrow 
with its effectors anillin, citron kinase, mDia, and ROCK (Nishimura Y et al. 2006, 
Piekny AJ et al. 2008, Glotzer M. 2001). Rho regulates the de novo actin 
polymerization and the dynamics of the actomyosin complex in the contractile ring. 
 
Actin is polymerized and its filaments are elongated at the leading front of the 
migrating cell, and depolymerized at the rear end focal contacts. The contractions of 
the actomyosin filaments move a migrating cell forward. At the rear end, Rho 
activates ROCK, leading to phosphorylation of the myosin light chain, contraction of 
the actomyosin filaments, and retraction of the rear of the cell (Riento K et al. 2003). 
ROCK is postulated to act also at the lateral sides of the cell in preventing 
inappropriate lateral protrusions (Worthylake RA et al. 2003). At the front of the cell, 
where excessive formation of contractile actin fibers needs to be restricted, the 
activity of Rho is controlled by Smurf1-dependent ubiquitination (Wang HR et al. 
2003). Recent studies have, however, revealed that local activation of RhoA takes 
 
 29 
place also at the edge of the protrusions and not only at the rear end of randomly 
migrating cells (Pertz O et al. 2006, Machacek M et al, 2009). The activity of RhoA 
in migrating cells is regulated by the localized activity of rhoGAPs, e.g. p190rhoGAP 
and DLC-1 (Kim TY et al. 2009, Bartolome RA et al. 2008). Furthermore, the 
relocalization of RhoA in migrating cells seems to be dependent on extracellular cues 
and the type of migration (Pertz O et al. 2006). Rho activates mDia1 in the front edge, 
leading to microtubule stabilization and alignment needed for migration. Rho-
dependent activation of mDia at the rear end recruits c-src to focal adhesions, 
resulting in rac activation and turnover of the focal contacts (Yamana N et al. 2006). 
Intracellular relocalization of Rho balances the contractility of actomyosin fibers and 
enables the directional movement of a cell, for instance during organogenesis and 
chemotaxis. 
 
Focal adhesions are macromolecular assemblies that attach cells to the extracellular 
matrix. The activation of Rho induces the assembly of focal adhesions by aggregation 
of vinculin and talin. The blocking of Rho activity, on the contrary, inhibits the 
assembly of actin stress fibers and focal adhesions (Ridley AJ et al. 1992). Detached 
and rounded cells, however, display high Rho activity which has been suggested to 
contribute to a more rigid actin cortex (Maddox AS et al. 2003). Rho participates also 
in the function of adherens junctions, which are involved in cell-cell contacts and in 
cytoskeletal dynamics. They convey extracellular signalling inside the cell and 
mediate mechanical forces. Rho proteins are postulated to function in the activity 
zones of adherens junctions where their activation and inactivation is balanced 
(Bement WM, et al. 2006, Yamada S, et al. 2007). Cadherins bind adjacent cells to 
each other in adherens junctions, and intracellular catenins link cadherins to the 
cytoskeleton (Hartsock A et al. 2008). The Rho-mediated formation and maintenance 
of adherens junctions is tightly regulated. Mechanical forces and signal transduction 
pathways of attachments activate Rho. Selective inactivation of Rho is mediated by 
rac1-recruited p120-catenin and p190rhoGAP (Wildenberg GA et al. 2006), and an 
adhesion-dependent negative feedback-loop maintains the balance of the Rho activity 
(Ren XD et al. 1999). p120-catenin binds Rho-GDP in adherens junctions and 
sequesters it from activation by GEFs; this leads to the local regulation of actin 




Rho GTPases are also involved in tumor initiation, progression and metastasis 
(Narumiya S et al. 2009). Rho proteins are usually not mutated in cancers, but their 
overactivity is found in a large variety of human tumors (Sahai E et al. 2002a). The 
elevated activity of Rho proteins in cancer cells might explain partly the increased 
motility of neoplastic cells. Enhanced expression of RhoC is screened from highly 
metastatic melanoma cells by DNA arrays. Furhermore, dominant-negative Rho 
inhibits metastasizing (Clark EA et al. 20009). Experiments performed with mutant 
Rho proteins in cultured cells suggest that they play a role in tumor initiation. 
Constitutively active forms of RhoA and Rac1 are able to induce cell transformation, 
whereas dominant-negative mutants of these proteins block ras-induced 
transformation (Qiu RG et al. 1995a, Qiu RG et al. 1995b, Prendergast GC et al. 
1995). The activity of Rho is high in ras-transformed cells, and it is considered a 
prerequisite for ras-induced transformation (Qiu RG et al. 1995b). ERK-MAP kinases 
activate Rho and also regulate the downstream signalling of Rho, thus promoting 
pathways of transformation (Sahai E et al. 2001). Increased proliferation occurs in 
tumor initiation. In addition to its inhibitory effect on inhibitors of cyclin-dependent 
kinases, Rho influences proliferation and the cell cycle by regulating ROCK and 
MEK/ERK. Active Rho enhances the activity of transcription factors (e.g. stat3, NF-
κB, serum response factor)  (Benitah SA et al. 2004, Montaner S et al. 1998, Benitah 
SA et al. 2003, Psichari E et al. 2002).  
 
Rho and ROCK activity is connected especially to a bleb-associated/ameboid mode of 
motility in which cells respond to chemo-attractants by relocating ezrin in a Rho-
dependent fashion, in the direction of movement. The elongated-cell-type of motility 
is less dependent on the activity of Rho/ROCK (Sahai E et al. 2003). In src-
transformed cells, which migrate in an elongated fashion, Rho is relocalized to 
podosomes. Rho may be needed for the formation of podosome structures implicated 
in tumor cell invasion (Berdeaux RL et al. 2004). The src-oncogene regulates the 
local activation and the cytosol-membrane cycling of Rho by inactivating the 
phosphorylation of Rho GDI (DerMardirossian C et al. 2006).  Smurf1, a ubiquitin 
ligase, induces degradation of Rho in the periphery of tumor cells and thereby 
regulates the formation of protrusions and the motility of the cells (Wang HR et al. 
2003, Sahai E, et al. 2007). In colorectal carcinoma cells, a low activity of Rho favors 
the maintenance of adherens junctions via mDia, whereas an increased activity of Rho 
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and ROCK promotes the collapse of junctions and enhances migration (Sahai E et al. 
2002b). The inhibition of RhoA by RNA interference or dominant-negative mutants 
has been found to attenuate the proliferation and tumorigenicity of gastric cancer cells 
and to enhance their sensitivity to chemotherapy (Liu N et al. 2004). A 
chemotherapeutic effect has also been achieved with a specific ROCK inhibitor, Y-
27632, which prevented the establishment of transplanted tumors in mice (Itoh K et 
al. 1999). The same inhibitor also abolished the metastasizing capacity of invasive 
prostate cancer cells in mice (Somlyo AV et al. 2000). 
  
3.2. The effect of polyamine regulation on the cytoskeleton 
 
Cells kept in polyamine-free culture and depleted of polyamines by inhibiting ODC 
activity lack normal actin fibers, thick stress fibers and microtubules (Pohjanpelto P et 
al. 1981, McCormack SA et al. 1994). Such cells may appear rounded with a 
considerably increased actin cortex and reduced lamellipodia, or elongated with a 
single thick actin bundle. The addition of polyamines restores the cytoskeleton and 
cell shape to normal. Inhibition of ODC not only distorts actin stress fibers, but also 
affects rER which perturbs the synthesis of proteins (Parkkinen JJ et al. 1997). Small 
multivalent cations, including polyamines, induce the bundling of actin fibers  (Sowa 
GZ et al. 2006) and also enhance the nucleation and elongation of microtubuli by 
facilitating the diffusion of tubulin  (Mechulam A et al. 2009). In rapidly dividing 
cells, phosphatidylinositol 4,5-bisphosphate mediates the effect of polyamine on actin 
nucleation  (Coburn RF et al. 2006).  An altered distribution of tropomyosin, a 
stabilizer of actin fibers, is found in polyamine-depleted cells (McCormack SA et al. 
1994). Furthermore, depletion of polyamines lowers the amount and activity of Rho 
and its downstream effector ROCK (Rao JN et al. 2003). Polyamines thus influence 
the dynamics of the cytoskeleton in various ways. In ras- and RhoA-transformed 
cells, the morphological changes are reversed by the inhibition of ODC activity 
(Shantz LM et al. 1998). A similar effect was detected in temperature-sensitive src-
transfected cells cultured in polyamine-depleted medium. Inhibition of ODC by 
treatment with DFMO blocked the src-induced depolymerization of filamentous actin 




Cells treated with DFMO also display inadequate attachment to the extracellular 
matrix and are incapable of spreading. Polyamine-depleted cells contain reduced 
amounts of focal adhesion kinase (FAK), and the phosphorylation of FAK and 
paxillin is inhibited (Ray RM et al. 2001). This leads to a failure to form protein 
complexes at the adhesion sites and prevents their binding to the actin stress fibers. 
Furthermore, polyamines are needed for integrin assembly and signalling in the 
adhesions.  
 
Johnson et al. have studied the role of polyamines in intestinal healing, in which the 
migration of enterocytes is a pivotal event. Wound healing and migration of intestinal 
epithelial cells (IEC-6) were inhibited by treatment with DFMO and the subsequent 
depletion of polyamines (Banan A et al. 1996, Ray RM et al. 2002). Exogenous 
polyamines were nevertheless able to restore the mobility of IEC-6 cells. Defects in 
the dynamics of the actin and microtubule cytoskeleton caused the migratory 
inhibition. Polyamine depletion reduced [Ca2+] mediated by voltage gated K+ 
channels leading to the inhibition of RhoA, ROCK, and phosphorylation of the 
myosin light chain  (Rao JN et al. 2003). Polyamines participate in the regulation of 
the cytoskeleton in normal proliferation and migration, as well as in malignant 
transformation. Polyamines are apparently involved in various signalling cascades in 
which Rho plays an important role.  
  
4. Polyamines and ODC in diseases 
4.1. Cancer 
 
If ODC is over-expressed in NIH 3T3 murine fibroblasts, the cells undergo 
transformation and show anchorage-independent growth in soft agar  (Auvinen M et 
al. 1992, Moshier JA et al. 1993). Inoculation of such ODC-overexpressing cells in 
nude mouse gave rise to highly-vascularized fibrosarcomas capable of invasive 
growth  (Auvinen M et al. 1997). ODC is surmised to function at the cross-roads of 
signal transduction pathways downstream of the oncogenes src, myc, and ras, 
including raf/ERK/MEK and PI3K pathways  (Hölttä E et al. 1993, Shantz LM 2004, 
Flamigni F et al. 1997, Auvinen M et al. 2003). In cells transformed by oncogenes or 
carcinogens, the activity of ODC remains constantly elevated  (Hölttä E et al. 1993, 
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Hölttä E et al. 1988, Gilmour SK et al. 1986). The inhibition of ODC activity by 
DFMO, however, retained the normal morphology of src-transformed cells, thus 
emphasizing the role of ODC and polyamines in the transformation process  (Höltta E 
et al. 1993). Experiments on transgenic mice have provided substantial evidence to 
support the participation of ODC and polyamines in tumorigenesis. The most studied 
model is skin tumorigenesis in these mice, in which ODC is expressed under the K6 
keratin promoter. The over-expression of ODC in these mice promotes tumor 
formation after their treatment with carcinogens, UV-radiation, or ras-activation  
(Pegg AE et al. 2003, Hayes CS et al. 2006, George K et al. 2005). Double-transgenic 
mice over-expressing both ODC and v-Ha-ras developed spontaneous tumors  (Smith 
MK et al. 1998). Oral administration of DFMO delayed the formation of skin tumors 
and regressed existing ones in transgenic mice over-expressing MEK1 under the 
keratin 14 promoter. This indicates that ODC activity is needed for the initiation and 
maintenance of tumors  (Feith DJ et al. 2005). However, ODC-transgenic mice in 
which ODC is under its own promoter and over-expressed in all tissues are not prone 
to spontaneous tumorigenesis in life-long surveillance with the exception of skin 
papillomas after two-stage chemical induction   (Alhonen L et al. 1995, Halmekyto M 
et al. 1992). Homozygous deletion of the ODC gene (knockout) is embryonally lethal. 
Haploinsufficient ODC+/- mice develop fewer tumors during their life-span as 
compared to their normal litter mates  (Guo Y et al. 2005). Over-expression of the 
ODC inhibitor, antizyme, in the skin of transgenic animals prevents carcinogen-
induced tumorigenesis  (Feith DJ et al. 2001). Elevated levels of polyamines have 
been measured in human colon, breast, and prostate cancers  (Leveque J et al. 2000, 
Mohan RR et al. 1999, Hixson LJ et al. 1993). Acetylated catabolic derivatives of 
polyamines in urine have been studied and used as a diagnostic marker for cancer  
(Inoue H et al. 2005). In addition, single-nucleotide polymorphism in ODC promoter 
is reported to predict a risk for colon polyps and cancer  (Martinez ME et al. 2003). 
 
The inhibitors of polyamine biosynthesis and polyamine analogs are the focus of 
study as potential chemotherapeutic agents. The ODC inhibitor, DFMO, lowers the 
concentration of putrescine and spermidine, and inhibits proliferation of malignant 
cells in cultures  (Prakash NJ et al. 1980). DFMO can be administered orally or 
peritoneally, and it is non-toxic  (Griffin CA et al. 1987, Abeloff MD et al. 1986). The 
efficacy of DFMO in clinical trials has, however, been disappointing. Polyamine 
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metabolism is regulated by various factors, and thus the inhibition of ODC has proved 
inadequate for achieving a significant decrease in the polyamine content of tumors in 
vivo. DFMO is now being studied in combination with non-steroidal anti-
inflammatory drugs as a potential chemopreventive agent of epithelial cancers  
(Meyskens FL Jr. et al. 1999, Meyskens FL Jr et al. 2009). Polyamine analogs, 
various forms of which have been synthesized, have a multi-level impact on 
polyamine metabolism, and thus seem to be more potent chemotherapeutic agents. In 
order to function efficiently as a chemotherapeutic agent, a polyamine analog needs to 
influence polyamine synthesis, catabolism and uptake. It can also be presumed that 
part of the efficacy is explained by the binding of polyamine analogs to the same 
structures as the naturally occurring polyamines  (for a review, see Casero RA Jr. et 
al. 2007).  Polyamines and their analogs are also used as vehicles to provide non-viral 
routes inside a cell for other chemotherapeutic and anti-parasitic compounds  (Holley 
JL et al. 1992, Delcros JG et al. 2006). 
 
4.2. Brain pathologies 
 
The induction of ODC activity results in increased concentrations of putrescine in the 
CNS. This is a general response to various physiological and pathological incidents, 
e.g. seizures, traumatic injuries, Alzheimer’s disease, ischemia, as well as chemical, 
radiation, and electrical stimulation.  
Experiments with mice and rats as well as studies on tissue cultures have shown that 
polyamines and ODC are connected to ischemic responses, especially during the 
reperfusion phase. Transient focal cerebral ischemia induces ODC activity, followed 
by accumulation of putrescine and depletion of the higher polyamines, spermidine 
and spermine  (Paschen W et al. 1991). This effect is particularly pronounced in the 
penumbra on the ipsilateral side of the ischemic lesion, but also in apoptotic cells of 
the hippocampus after mid-cerebral artery occlusions  (Baskaya MK et al. 1997, 
Sauer D et al. 1992, Muller M et al. 1991, Maeda M et al. 1998, Keinänen R et al. 
1997). The same phenomenon has been detected also in ischemic heart  (Zhao YJ et 
al. 2007, Zhao YJ et al. 2009). These findings have led to the assumption that ODC 
induction provokes the onset of ischemic damage and that putrescine mediates 
cytotoxic effects in neurons. However, experiments with transgenic animals that over-
express ODC provide a different picture, pointing to a neuroprotective role of 
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polyamines and ODC. The infarct volume was smaller and the reperfusion damage 
developed more slowly than in the wild-type littermates or DFMO-treated animals 
(Lukkarinen JA et al. 1998, Lukkarinen JA et al. 1999). Long-lasting up-regulation of 
ODC expression was detected also in areas where no reperfusion lesions had 
developed. Intracranial infusion of putrescine has even been reported to provide 
protection against ischemia-induced neuron death  (Keinänen R et al. 1997, Gilad GM 
et al. 1991). Results reinforcing the neuroprotective role of polyamines were obtained 
from experiments on rat brains subjected to continuous infusion of antisense 
oligonucleotide to ODC during transient mid-cerebral artery occlusion. Inhibition of 
ODC predisposed the animals to increased infarct volume, motor deficit, and 
mortality (Raghavendra Rao VL et al. 2001). Maternal hypoxia elevated the activity 
of ODC and the concentration of polyamines in the brain of mouse embryos. 
However, no neurotoxic effects were detected in the embryonal brain  (Longo LD et 
al. 1993). Spermine, but not putrescine or spermidine, had a protective role in primary 
cultures of hippocampal and pyramidal neurons. It promoted the survival of neurons 
in a NMDA-dependent fashion and served as a scavenger of free radicals (Abe K et 
al. 1993, Ha HC et al. 1998). This indicates that different polyamines have specific 
functions. Furthermore, the effect of polyamines on the development of ischemic 
lesions is postulated to depend on the NMDAR activity: antagonists of NMDAR 
blocked the ischemia-induced activation of ODC, and inhibition of ODC prevented 
NMDAR-induced cytotoxicity  (Keinänen R et al. 1997, Markwell MA et al. 1990). 
In conclusion, ODC and polyamines contribute to the modulation of ischemic brain 
trauma. There is still controversy, however, regarding the exact mechanisms, as well 
as the ultimate role that polyamines play in neuroprotection and cytotoxicity. 
 
The expression and activity of ODC is locally increased in Alzheimer’s disease  
(Bernstein HG et al. 1995, Morrison LD et al. 1998). Accumulation of spermidine has 
been found together with reduced levels of putrescine and S-adenosylmethionine, 
indicating enhanced synthesis of higher polyamines  (Morrison LD et al. 1995, 
Morrison LD et al. 1996). Immunohistochemistry of diseased brain tissue has 
revealed accumulation of ODC in neocortical pyramidal cells and interneurons. Not 
only the amount of protein seemed to be elevated, but also the number of ODC-
positive cells was increased  (Bernstein HG et al. 1995, Nilsson T et al. 2006a). 
Furthermore, ODC was intracellularly redistributed. The normal nuclear and 
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perinuclear localization of ODC was spread more diffusely in the cytoplasm of 
neocortical, hippocampal, and Purkinje neurons in AD  (Nilsson T et al. 2006a). ODC 
was detected also in the dendrites and axons of cortical pyramidal cells in AD brains, 
contrary to that of normal brain tissue  (Bernstein HG et al. 1995).  
 
 
Aberrant accumulation of β-amyloid into the extracellular space is considered 
important in the pathogenesis of AD. Activation of the β-amyloid precursor protein, 
which functions as a cell surface receptor, causes a rapid increase in the expression of 
ODC  (Nilsson T et al. 2006b). β-amyloid accelerates the generation of reactive 
oxygen species (ROS), and this in turn induces ODC activity and the production of 
polyamines  (Yatin SM et al. 1999). The uptake of polyamines is also upregulated by 
β-amyloid stimulation which, together with increased ODC activity suggests an 
underlying induction of AZIN.  The generation of ROS is enhanced by the binding of 
β-amyloid oligomers to NMDARs, and is dependent on NMDAR activity  (De Felice 
FG et al. 2007). Activation of NMDAR upregulates the expression of ODC in 
cultured neuronal cells  (Nilsson T et al. 2006a). Simultaneously, β-amyloid disturbs 
NMDAR-mediated long-term potentiation in the hippocampus and interferes with 
down-stream signalling of NMDAR  (Yamin G 2009). Polyamines regulate NMDAR 
activity in various ways, mostly by enhancing ligand binding  (Araneda RC et al. 
1999, Benveniste M et al. 1993). A positive feedback loop is formed between ODC 
and NMDAR, since NMDAR has been found to stimulate ODC activity leading to 
enhanced synthesis of polyamines, which in turn amplify NMDAR signalling. Further 
evidence supporting functional coupling between ODC and NMDAR was obtained 
from ODC transgenic mice with impaired performance in spatial learning and 
memory  (Halonen T et al. 1993), i.e. functions regulated by NMDAR signalling. 
Whether polyamines are neuroprotective or neurotoxic in AD is still unsolved. 
Nevertheless, ODC transgenic mice which have high ODC activity and putrescine 
levels, do not develop more age-related neurodegenerative changes in neurons or 
brains than their wild-type littermates  (Alhonen L et al. 1995).  This suggests that 
ODC activation itself does not have deleterious effects, but is rather an adaptive 
response to noxious stimuli. The accumulation of spermine in AD might indicate an 
attempt to neutralize free radicals formed by the overactivity of β-amyloid  (Yatin SM 
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et al. 2001). There is evidence of the involvement of polyamines in other 
neurodegenerative diseases, e.g. Parkinson’s disease, in which spermine enhances the 
aggregation of α-synuclein (Grabenauer M et al. 2008).  
 
The overall view of polyamines and ODC in brain pathology is in favor of 
neuroprotective responses to pathological events, despite numerous controversial 
findings. Therapeutic interventions using the polyamine system have not advanced, 
however, except for the use of memantine in AD. Overactivity of NMDAR leading to 
cytotoxicity is prevented by memantine which interferes with the polyamine binding 




AIMS OF THE STUDY 
 
The aim of this study was to investigate the functional factors involved in the 
regulation of polyamines and ornithine decarboxylase, and to search for a mechanistic 
link between the polyamine system and the dynamics of the actin cytoskeleton. The  
specific aims were: 
 
− to investigate the polyamination of a small G protein, RhoA and the role of  
transglutaminase in polyamination 
− to evaluate the relevance of polyamination in proliferation and transformation 
− to investigate the influence of ODC activity and localization on RhoA 
regulation 
− to characterize a novel ODC homolog from human brain 
− to investigate the tissue-specific expression of AZIN2 
− to gather basic knowledge of AZIN2 in order to determine its functional role. 
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MATERIAL AND METHODS 
The material and methods used in this thesis work are described in detail in the 
original publications. The table below summarizes the methods used with a referral to 
the respective publication. 
  
Method Publication 
Antibody production III, IV 
Cell culture I, II 
Cell cycle synchronization I 
cDNA cloning I, II 
DNA histogram (flow cytometry) I 
DNA purification I-IV 
DNA sequencing I - IV 
Dot blot  II 
Fractionation of cells I 
Immunohistochemistry III, IV 
Immunofluorescence stainings I, IV 
Immunoprecipitation I 
In vitro translation II 
In situ hybridization III, IV 
Metabolic labeling I 
Microscopy, confocal I 
Microscopy, epifluorescence I, IV 
Light microscopy  I, III-IV 
ODC-assay I, II 
PCR I, II,  
RT-PCR II, IV 
Transfection I - IV 
Transformation assay I 
SDS-PAGE I, II 
Sequence alignment I 
Site-directed mutagenesis I 
Validation of antibody III, IV 
Western blotting / SDS-PAGE I-IV 
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RESULTS AND DISCUSSION 
1. ODC and the cytoskeleton 
1.1. Transglutaminase mediates polyamination of RhoA 
 
The physiological polyamination of RhoA was studied in murine fibroblast cell lines 
(NIH 3T3 and Rat1 tsRSVLA29), and in a cell line of Chinese hamster ovary in 
which the ODC-protein was mutated and catalytically inactive (C55.7, called CHO 
ODC- in these studies). The CHO ODC- cell line was further transfected with active 
ODC (CHO ODC+), and with ODC incapable of membrane translocation (CHO 
PHOX). All of the above-mentioned cell lines were metabolically labeled with 14C-
putrescine or 14C-spermidine. Separated cell lysates were visualized with both an 
antibody to RhoA and by autofluorography. Western blotting revealed two closely 
spaced bands, but only the faster moving band incorporated labeled polyamines. 
Furthermore, from the same cell lysates, RhoA was immunoprecipitated, and after 
SDS-PAGE and autofluorography, binding of labeled polyamines to RhoA was 
detected (I, Fig 1A). The results are in accordance with those of Masuda and 
coworkers, who have earlier reported that polyaminated RhoA displays faster 
mobility on SDS-PAGE than does unmodified RhoA (Masuda M et al. 2000). It is 
noteworthy that the peptide antibody used in our studies detects not only RhoA, but 
also RhoC, the function of which is less characterized but considered to be similar to 
that of RhoA. Therefore the possibility that RhoC also might be polyaminated cannot 
be ruled out. Polyamination of RhoA has previously been detected in vivo only in the 
presence of exogenous transglutaminase (Bordetella dermonecrotizing toxin) which 
catalyses polyamination of RhoA by covalent cross-linking of putrescine and 
spermidine to Gln63 (Masuda M et al. 2000, Shin DM et al. 2008). This modification 
activates RhoA by inhibiting its intrinsic and extrinsic GTPase activity, and leaves the 
G protein in a constitutively active, GTP-bound configuration. Earlier, the 
polyamination of RhoA has been shown only with additive transglutaminases, 
whereas in the present studies the polyamination was detected in all cell lines tested 
without addition of exogenous transglutaminases. Differences in the relative amounts 
of polyaminated RhoA were, however detected between cell lines, which might 
explain the discrepancy in detecting physiological polyamination of RhoA. In 
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addition, the detection of the polyamination of RhoA proved to be inaccurate from 
frozen and thawed samples. Only fresh prepared samples were thus used in the 
studies. 
 
To further study the role of transglutaminase activity for the polyamination of RhoA, 
Rat1 tsRSVLA29 and CHO ODC+ cells were treated with 0.2 mM 
monodansylcadaverine (MDC), an inhibitor of tissue transglutaminase 2 (TG2). 
Western blotting of lysates from MDC-treated cells revealed greatly reduced amounts 
and even an absence of fast-moving, polyaminated RhoA (I, Fig 1B). This indicated 
that the catalytic activity of transglutaminase was needed for the polyamination of 
RhoA and further confirmed that the faster moving band of RhoA was modified by 
polyamination. These results are in accordance with the findings of Singh et al. who 
have earlier shown that the transamidation of RhoA is prevented by inhibiting the 
activity of transglutaminase (Singh US et al. 2001). Recently, the inhibition of TG2 
and the following reduction in the polyamination of RhoA have been shown to 
prevent also the interaction of RhoA with its downstream effector, ROCK (Shin DM 
et al. 2008).  
 
Transamidation activity of TG is dependent on high [Ca2+], and such a concentration 
has been linked only to pathological states. However, the present results suggest the 
transamidation of RhoA by polyamines to take place in physiological states including 
proliferation. Most likely high concentration of Ca2+ is achieved by local regulation.  
 
1.2. Polyamination of RhoA and the cell cycle 
 
Changes in the relative amounts of polyaminated RhoA were investigated in lysates 
collected at various stages of the cell cycle from synchronized NIH 3T3 cells. 
Western blotting with polyclonal antibody against RhoA revealed changes in the 
proportion of intact versus polyaminated RhoA. Faster moving, polyaminated RhoA 
dominated in cells entering the G2/M phases when the incorporation of radio-labeled 
spermidine was also detected by SDS-PAGE and autofluorography (I, Fig 2B). In 
contrast, unmodified RhoA was abundant during G1 and S. The impact of RhoA 
polyamination on the progress of the cell cycle was also studied in Jurkat cells treated 
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with two inhibitors of TG2 (0.2 mM MDC or 0.2 mM cystamine) for three days prior 
to flow-cytometric analysis. Inhibition of TG2 induced a relative block between 
G2/M and G1, with an increase from 6% to 29% of the cell population (with MDC) in 
G2/M without accumulation in G1 (I, Fig 2E). Overexpression of RhoA by a transient 
transfection sensitized these cells to a relative cell cycle block induced by inhibitors 
of TG2. Similarly, a reduction in the amount of polyaminated RhoA, obtained by 
transfecting the cells with a polyamination-deficient mutant of RhoA, RhoA-Q63A, 
blocked the cell cycle. 70% of the cells accumulated in G2/M. Treatment with 
inhibitors of transglutaminase 2 had no further effect on the accumulation of cells 







 G1           S   G2/M 
Figure 3. The concentration of polyamines and the activities of their metabolizing 
enzymes fluctuate during the cell cycle. Polyamination of RhoA is detected 
simultaneously with the elevated amount of polyamines in G2/M phases. 
 
MDC and cystamine are amines that inhibit transglutaminase by competitive binding, 
although cystamine also directly inhibits transamidation. The activity of ODC and the 
relative amount of spermidine were measured from the cell lines used in these 
experiments in order to exclude the possibility that the detected cell cycle block was 
caused merely by the reduced polyamine synthesis induced by these compounds 
acting as polyamine analogs. No decrease in the activity or in the content of 
spermidine was detected in Jurkat or CHO ODC+ cells after treatment with MDC or 
cystamine (I, supplementary material). This proved that the effects of the compounds 
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were due solely to the inhibition of TG2.  Since MDC decreased slightly the activity 
of ODC and also the content of spermidine in Rat1 tsRSVLA29 cells, only cystamine 
was used to treat this cell line. 
 
These results show that the extent of polyamination of RhoA alters during the cell 
cycle, and that the fluctuation is required for proper progress of the cell division. In 
mitosis, RhoA affects centrosome positioning (Rosenblatt J et al. 2004) and is 
involved in creating contractile forces at the cleavage furrow during cytokinesis 
(Glotzer M 2001). It is conceivable that the activation of RhoA by polyamination 
during the G2/M phase is related to these functions.  
 
1.3. Polyamination of RhoA and transformation 
 
RhoA by itself is not a transforming protein, but it enhances migration and invasion of 
ras and src-transformed cells (Sahai E et al. 2003, Sahai E et al. 2001). To investigate 
the functional impact of the polyamination of RhoA on cell transformation, Rat-1 
cells (Rat1 tsRSVLA29) were infected with a temperature-sensitive mutant of v-src 
(ts-v-src). Hölttä et al. have previously shown that the depletion of polyamines 
inhibits the ts-v-src-induced transformation at a permissive temperature, whereas the 
addition of exogenous polyamines restores the transformation (Höltta E et al. 1993). 
We compared the transforming capability of Rat1 tsRSVLA29 cells cultivated in the 
presence or absence of 0.25 mM cystamine. The control cells underwent 
morphological transformation at a permissive temperature, whereas the rate of 
transformation (I, Fig 4) and the polyamination of RhoA (I, Fig 1B) were repressed in 
cells treated with the TG2 inhibitor cystamine. These cells were sensitive for the over-
expression of RhoA or RhoA-Q63A. Transiently transfected cells acquired a rounded 
morphology even at a non-permissive temperature and were detached more easily 
from the culture plate. Rounded cell morphology has previously been linked to the 
activity of RhoA and ROCK (Sahai E et al. 2003). Rounding of cells has also been 
detected in v-src transformed mouse fibroblasts transfected with constitutively active 
RhoA, RhoA-Q63L. The activity of RhoA (and RhoC) was spatially regulated in 
these cells and accumulated in the cortical ring of actin (Berdeaux RL et al. 2004). 
The present results are in accordance with these findings, and suggest that RhoA is an 
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important player in v-src-induced cell transformation, and that polyamination 
regulates the activity of RhoA. 
 
1.4. ODC-mediated spatial regulation of RhoA and reorganization of 
actin  
 
CHO ODC- cells and their derivatives CHO ODC+ and CHO PHOX were used for 
studying the impact of ODC on the spatial regulation of RhoA. Mutation of the 
p47PHOX motif impairs the membrane translocation of ODC upon cell activation 
(Heiskala M et al. 1999). In addition, NIH 3T3 cells were transfected with an 
antisense oligonucleotide to AZ1 and Rat1 tsRSVLA29 cells with a polyamination-
deficient mutant of RhoA (RhoA-Q63A). The reorganization of actin was investigated 
in these cells. The cell lines were cultivated in the absence of polyamines for three 
days and stimulated by hypo-osmotic stress to enhance the ODC activity (Poulin R et 
al. 1990) with the exception of Rat1 tsRSVLA29 cells.  
 
Western blotting of total cell lysates revealed a robust polyamination of RhoA in 
CHO ODC+ cells (I, Fig 3A). The polyamination was less efficient in NIH 3T3 and 
Rat1 tsRSVLA29 cells, suggesting differences in the activity of TG2 between the 
different cell lines. In cells with normally inducible ODC activity and with ODC 
capable of membrane translocation, the reorganization of actin responded to changes 
in the activity of ODC. The induction of ODC by hypo-osmotic stress resulted in the 
formation of actin stress fibers which depolymerized when the activity of ODC 
declined (unpublished results from the present studies, Fig 4). Furthermore, no defects 
were observed in the progression of the cell cycle. Interestingly, NIH 3T3 cells with 
constitutively high ODC activity obtained by treatment with AZ1-antisense 
oligonucleotide were rounded, loosely attached, and lacked actin stress fibers 
(unpublished data).  
 
The relative amount of polyaminated RhoA was lower in CHO PHOX cells, and 
especially in CHO ODC- cells compared to the CHO ODC+ cell line. The treatment 
of CHO ODC+ cells in polyamine-free medium with DFMO increased the amount of 
non-polyaminated RhoA (I, Fig 3B). This shows that catalytically active ODC and 
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ODC capable of membrane translocation are needed for the efficient polyamination of 
RhoA in the absence of external polyamines. Nevertheless, the polyamination of 
RhoA was not totally prevented by inhibition of the ODC-activity suggesting that the 
polyamination is not entirely dependent on ODC-activity. Ray et al. have shown that 
inhibition of ODC by DFMO decreases the activity of RhoA that is recovered by the 
addition of putrescine (Ray RM, et al. 2002). This is in accordance with present 
results of the roles of ODC and TG2 for the polyamination of RhoA.  
  
The formation of actin stress fibers as a response to hypo-osmotic stress was 
repressed in CHO ODC- cells. In CHO PHOX cells, the reorganization of actin was 
delayed: stress fibers appeared later and resolved more slowly (unpublished results, 
Fig 4).  The reorganization of actin was also disturbed in Rat1 tsRSVLA29 cells 
transfected with polyamination-deficient RhoA (RhoA-Q63A). These cells were 
rounded and loosely attached. The findings on stress fiber reorganization emphasize 
not only the importance of ODC-induction for the regulation of RhoA and actin 




Figure 4. The formation of actin stress fibers after 4 hours of hypo-osmotic shock. 
The cells were cultivated in polyamine-free media, and actin is visualized by 
rhodamine phalloidin staining. 
Analysis of the membrane and cytoplasmic fractions of CHO PHOX cells showed 
that the membrane fraction was devoid of ODC activity and, interestingly, also of 
both intact and polyaminated RhoA (I, Fig 3C). Only ubiquitinated forms of RhoA 
were found in the membranes of CHO PHOX cells. In CHO ODC+ cells both active 
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ODC and polyaminated RhoA were detected in the membrane fraction. However, if 
CHO ODC+ cells were treated with a synthetic peptide RLSVKFGA, which 
corresponds to the p47PHOX motif of ODC and prevents its membrane translocation 
(Heiskala M et al. 1999), both ODC activity and RhoA were absent from the 
membrane fraction (data not shown).  
 
In CHO ODC+ cells cultured in the presence or absence of polyamines, confocal 
immunofluorescence microscopy with an antibody to RhoA revealed a concentration 
of RhoA close to the plasma membrane. In CHO PHOX cells, RhoA displayed a 
diffuse cytoplasmic distribution (I, Fig 3D). Some accumulation of RhoA was seen in 
the vicinity of the plasma membrane in CHO ODC- cells, but most of it remained 
dispersed over the cytoplasm. Analysis of CHO ODC+ cells transfected with RhoA-
Q63A showed an accumulation of RhoA beneath the plasma membrane (I, Fig 3E). 
These findings demonstrate that an intact membrane translocation of catalytically 
active ODC is a prerequisite for the distribution of RhoA to the membrane actin 
cytoskeleton. It has been previously reported that inhibition of the ODC-activity 
decreased the amount of RhoA in the membrane fraction by 27% (Ray RM et al. 
2002). However, the ODC-regulated spatial distribution of RhoA is independent of 
the polyamination of RhoA. 
 
2. The structure and distribution of AZIN2 
2.1. Comparison of the structures of ODC and AZIN2 
 
As AZINs are considered to have emerged via gene duplication of ODC, the 
homology between these proteins is high. The identity between AZIN2 (SV1; 
formerly named ODC-paralogue, ODC-p) and ODC is 54%, and the similarity is 
75%. The corresponding values for AZIN2 and AZIN1 are 45% and 66%, 
respectively (II, Fig. 2). 
 
ODC is fully active only as a homodimer, and it has two active sites at the interphase 
of the monomers. Using crystallographic and biochemical assays, Albeck et al. (2008) 
showed that AZIN1 appears as a monomer under physiological conditions). Recently, 
the amino acids crucial for the lack of dimerization of AZIN1 were determined to be 
 
 47 
Ser 277, Ser 331, Glu 332, and Asp 389 (Su KL, et al. 2009). Even though no data yet 
exist on the nature of AZIN2 dimerization, the amino acids Ser 277 and Ser 331 are 
also dissimilar in AZIN2 compared to ODC. While dimerization of ODC is needed to 
induce the enzymatic activity, there is no reason to assume that enzymatically inactive 
AZIN2 would appear as a dimer. 
 
The catalytically active site of ODC is combined of residues from the N terminus of 
one monomer and the C terminal residues of the other monomer (Tobias KE et al. 
1993). The most important residues for ODC activity are K69, C360, and D361 
(Tobias KE et al. 1993, Osterman AL et al. 1995, Coleman CS et al. 1993). Variants 
mutated by these amino acids reveal that each one is required for full catalytic 
activity. These residues contribute to the binding of the substrate, and K69 is also 
involved in the binding of the co-factor pyridoxal-5'-phosphate (PLP). C360 appears 
to mediate the binding of DFMO. The residues associated with the catalytic activity 
of ODC, K69, E94, K115, K169, H197, D233, E274, D361, and D364 (Osterman AL 
et al. 1995, Coleman CS et al. 1993, Tsirka S et al. 1992) are conserved in AZIN2, 
whereas D88 and C360 are not. C360 is conserved in ODC throughout the variety of 
species, from bacteria to eukaryotes. The ODC mutants C360A and C360S are almost 
devoid of decarboxylation activity (Tobias KE et al. 1993, Coleman CS et al. 1993). 
These mutated enzymes, however, catalyze a decarboxylation-dependent 
transamination reaction to form pyridoxamine-5-phosphate and γ-
aminobutyraldehyde, indicating a role for C360 in controlling the specificity of the 
reaction (Jackson LK et al. 2000). In AZIN2, C360 is replaced by a hydrophobic 
valine, whereas in AZIN1, C360 is conserved. Biochemical studies have nevertheless 
shown that both AZINs are devoid of decarboxylating activity on ornithine 
(Murakami Y et al. 1996a, Kanerva K et al. 2008). 
 
The translocation of ODC to the membrane cytoskeleton is necessary for it to function 
optimally (Heiskala M et al. 1999). The p47phox-like motif, which is responsible for 
the translocation, is conserved almost entirely in AZIN2. The distribution of AZIN2 
has been linked to membrane fractions in mouse brain and to vesicles in mast cells 
(Lopez-Contreras AJ et al. 2006, Kanerva K et al. 2009). Furthermore, the present 
results on the localization of AZIN2 in the human brain and testis also suggest that it 
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is adjacent to membranes. So far, however, there are no data available on the 
functionality of the p47phox-like motif in AZIN2. 
 
The rapid degradation of ODC in proteasome 26S is induced by binding to AZ 
(Murakami Y et al. 1992, Murakami Y et al. 1996b). AZ binds to ODC via a specific 
binding domain (residues 117-140), which is highly homologous in both AZIN2 and 
AZIN1 (I, Fig. 2). AZINs are capable of displacing ODC from the AZ-ODC complex 
because of their higher affinity (Snapir Z et al. 2008, Fujita K et al. 1982). AZ binding 
alone is not sufficient for ODC turnover; two PEST regions in the C-terminus are also 
needed for the targeting and degradation by proteasome 26S (Li X et al. 1993). The 
homology between AZINs and ODC decreases towards the C-terminus, and no PEST 
region is recognized in the C-terminal part of AZINs  
(http://www.Icnet.uk/LRITu/projects/pest/). The ODC protein is known to be 
stabilized by truncation of its C-terminus (Ghoda L et al. 1989), suggesting that the C-
terminal PEST domains are essential for the turnover of ODC. Furthermore, the 
electron-dense N- and C-termini of AZIN1 are in closer contact with each other than 
in ODC, indicating functional differences in these regions (Albeck S et al. 2008).  
  
 
2.2. Alternative splicing of AZIN2 
 
Alternative splicing is a normal phenomenon in eukaryotes; it increases the diversity 
of proteins that can be encoded by a limited number of genes.  In humans, over 80% 
of the genes are alternatively spliced enabling encoding of several proteins by a single 
gene, rather than requiring a separate gene for each polypeptide (Black DL 2003). 
Alternative splicing has been found to be especially active among genes expressed in 
human brain (Black DL et al. 2003). 
 
Ten alternatively spliced forms of the coding region of AZIN2 have been detected by 
sequencing with specific primers to exon I and IX or XI from a QUICKclone cDNA 
(Clontech) of human brain and testis (II, Table I). The four longest splicing variants 
(SV) are SV1, 2, 9, and 10, which terminate in exon XI, and are combined of exons as 
shown in Table 1. A 60-bp extension at the 5´ end of exon VIII and a 84 bp-exclusion 
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from the 5´ end of exon V distinguish the otherwise identical SV2 and SV9 from 
SV1, respectively. As compared to SV8, in SV10, exon II includes a 93-bp extension 
at the 5´end.  
Table 1. The variability of the exon composition of AZIN2. The exons of each splicing 
variants determined by sequencing the clones are marked (√).*60-bp extension in the 
5'-end. **37-bp extension in the 5'-end. † exon length 51-bp (shorter from 5'-end). ‡ 

























SV1 √  √ √ √ √ √ √  √ √ 
SV2 √  √ √ √ √ √ √ *  √ √ 
SV3 √  √ √ √ √ √ √ √   
SV4 √  √ √ √ ** √ √ √ √   
SV5 √  √  √ √ √ √ √   
SV6 √  √    √ √ √   
SV7 √     √ √ √ √   
SV8 √ √ √ √ √ √ √ √ √   
SV9 √  √ √ √† √ √ √  √ √ 
SV10 √ √‡ √ √ √ √ √ √  √ √ 
 
Splicing variants 3 through 8 terminate in exon IX: their exon structures are shown in 
Table 1. Exon IX contains a premature stop codon. This exon is not transcribed in the 
most abundant RT-PCR product from the brain and testis, and the majority of the 
ESTs do not include it. Nevertheless, the occasional transcription of exon IX is 
verified by its presence in rare ESTs from squamous cell lung carcinoma and 
brain/mixed tissue-derived libraries. By using a 3´ primer designed for exon IX, six 
different, alternatively spliced variants (SVs 3 through 8) could be amplified from 
testis tissue.  
 
The sequences of SVs 1–2 and 9–10 were obtained from a pool of human brain 
mRNA, whereas SVs 1-8 were sequenced from a testis pool. The existence in vivo of 
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the described SVs was not systematically screened in brain and testis, but rather the 
sequences of different variants emerged during the cloning of AZIN2. Thus, the 
expression pattern of these variants in different tissues is still to be discovered. 
Although not specifically tested, the predominance of SV2 and especially of SV1 over 
the other variants has become apparent through repetitive sequencing of the mRNA 
pools.  
 
The coding region of AZIN2 SVs 1, 2, 3, 7, 8, and to a lesser extent of SV5, were 
effectively translated in our system (II, Fig. 1C). Autoradiographic visualization 
showed approximately the size of 51 kDa for SV2, which agrees with the predicted 
protein sequences. SDS-PAGE analysis revealed that SVs 1, 3, 7, and 8 showed bands 
of apparent sizes of 46 kDa, 42 kDa, 40 kDa, and 44 kDa, respectively. As we have 
not in vitro translated the SVs 9 and 10, their translation to proteins in vivo remains to 
be shown. In silico translation of the splicing variants implies a premature stop-codon 
in SV7, whereas the reading-frame of the other variants remains open in spite of 
alternative splicing. 
 
According to current knowledge, the principal function of AZIN2 is the binding and 
inactivation of AZ (Kanerva K et al. 2008, Lopez-Contreras AJ et al. 2006, Snapir Z 
et al. 2008a). The presence of an AZ-binding site is a prerequisite for its function. A 
comparison of the AZIN2 sequence to that of the ODC gene, in which the AZ-binding 
site is characterized, indicates the absence of this motif from SVs 5-7 and 9. This 
implies that these variants of AZIN2 are incapable of binding and inactivating AZs. In 
addition to the AZ-binding site, the p47PHOX motif was detected from SVs 1–5 and 8–
10, although its functional significance in AZIN2 remains to be settled. The splicing 
variants lacking the AZ-binding site may be futile products of the spliceosome. 
However, they may also represent non-coding RNAs which are not intended to be 
translated but rather to regulate the translation process. 
 
The structural homologs and functional counterparts of AZIN2, ODC and AZIN1 are 
not alternatively spliced to the extent of AZIN2. The long 5’-untranslated region 
(UTR) of ODC is alternatively spliced to a short form in pancreatic tumor cells 
enabling an internal ribosomal entry site and fast, cap-independent translation. This 
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variant of the ODC transcript is more sensitive to cell-cycle changes (Pyronnet S et al. 
2005).  
 
Two antisera were raised in rabbits to AZIN2 by using the synthetic peptides 
STRDLLKELTLGASQATTDEVA (antiserum 2) and STRDLLKELTLGASQATT 
(antiserum 3), corresponding to amino acids 18–39 and 18–35 of AZIN2 sequence 
(RefSeq Accession NM_052998) as immunogens. The longer peptide spans from 
exon 1 to exon 3, leaving out exon 2 which is not included in the splicing variants 1–7 
and 9. The shorter peptide is encoded only by exon 1, thus being capable of 
recognizing all splicing variants, including variants 8 and 10 (IV, Fig S1). Another 
peptide antibody against rodent AZIN2 produced by López-Contreras et al. (2008b) is 
designed to recognize the boundary between exons 8–10, and therefore leaves out 
SVs terminating in exon 9.  
 
Two peptide antibodies differed in their ability to detect AZIN2 in different 
subcellular compartments. In brain, antiserum 3 detected a strong expression of 
AZIN2 in axons. It also stained pyramidal neurons of the neocortex with a lower 
intensity. Antiserum 2, in turn, recognized AZIN2 in the soma and apical dendrites of 
pyramidal neurons but not the axon-localized AZIN2 (IV, Fig 1). Testicular 
expression of AZIN2 detected by antiserum 3 was concentrated in Leydig cells, and 
to a lesser extent reacted with spermatogonial cells of seminiferous tubuli (III, Fig 1). 
Again, the distribution detected by antiserum 2 was more restricted; only 
spermatogonial cells were stained (unpublished data). It is surmised that this variation 
in the staining pattern was caused by the selective specificity of the antisera for 
different splicing variants of AZIN2. López-Contreras et al. (2008b) have reported the 
expression of AZIN2 in haploid germ cells of mouse testis, but they presented no data 
on the expression of AZIN2 in mouse Leydig cells. The seemingly discrepant findings 
on the distribution of AZIN2 in testis obtained with the present antibodies to the N-
terminus and the C-terminal antibody of López-Contreras et al. can be explained by 
their reactivity with different SVs of AZIN2 reflecting biological differences between 




The presence of several splicing variants of AZIN2 in human brain was demonstrated 
by RT-PCR with primers to exon I and XI (IV, Fig 2A), and further confirmed by 
western blotting with antiserum 3 against AZIN2. Two strong bands of AZIN2 were 
detected from the white matter, while an additional band of apparently larger size 
dominated in the blottings from the gray matter (IV, Fig 2B).  
 
Taken together, these results indicate that differently spliced variants of AZIN2 occur 
in the CNS and testis. Furthermore, these data suggest an anatomically divergent 
distribution of the different splicing variants of the protein. The functional role of 
these splicing variants of AZIN2 remains to be elucidated, but it is possible that the 
variants target their expression to specific cellular or sub-cellular distribution. 
 
2.3. Tissue distribution of AZIN2 
 
Whereas ODC is expressed in all types of living cells, with exception for certain 
archaea, the expression of AZIN2 seems to be restricted to higher eukaryotes (Homo 
sapiens, Pan troglodytes, Canis lupus familiaris, Bos taurus, Mus musculus, Rattus 
norvegicus, and Gallus gallus) as evaluated by HomoloGene, NCBI 
(http://www.ncbi.nlm.nih.gov/homologene/). In Xenopus laevis, the expression of an 
ODC homolog (XODC2) has been characterized, and that protein is presumably an 
AZIN2, as judged by its sequence homology (Kidron H et al. 2007). The expression 
of XODC2 in fetal frog is more restricted than XODC and is located e.g. in the 
forebrain (Cao Y et al. 2001). 
 
The transcription of AZIN2 was studied using mRNA Multiple Tissue Expression 
(MTE) array, RT-PCR, northern blotting, and in situ hybridization. With all these 
techniques, a high expression of AZIN2 was detected in brain and testis. In the MTE 
array, including samples from altogether 21 specified regions of human central 
nervous system, expression of AZIN2 was detected widely. Even greater amounts of 
AZIN2 transcripts were probed from testis (II, Fig 3). The expression of ODC was 
detected in all the tissues, although only moderate binding of the probe was seen in 
the dots from CNS. A similar expression pattern of AZIN2 was described by Lopez-
Contreras et al. (2006) in mouse tissues. Using quantitative PCR, they also showed a 
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predominance of AZIN2 over AZIN1 in mouse brain and testis, suggesting a 
compensatory regulative role for these homologs (Lopez-Contreras AJ, et al. 2008a). 
In addition, we have investigated the expression of AZIN2 by northern blotting of 
total RNA isolated from newborn and adult rat brain and testis. The expression of 
AZIN2 remained low/moderate in newborns compared to a more abundant expression 
in adult rat tissues (unpublished data). In mouse testis, the expression of AZIN2 was 
increasing on postpartum day 22, being nearly absent in newborns and increasing 
towards adulthood (Lopez-Contreras AJ et al. 2008b). Regunathan et al. (2000) 
studied the expression of AZIN2 in rat brain, although they falsely called AZIN2 
arginine decarboxylase (ADC). They measured the amount of mRNA and protein, and 
concluded that AZIN2 (ADC in their study) was expressed in all parts of the brain. In 
accordance with the present results and those of Lopez-Contreras, they showed an 
increase in the expression of AZIN2 upon neuronal differentiation. The expression 
data from mRNA samples invariably shows restricted distribution of AZIN2, which 
differs from the ubiquitous expression of ODC and AZIN1. This further suggests 
some restriction in the function(s) of AZIN2. 
 
With two validated polyclonal peptide antibodies, the presence of AZIN2 was 
screened by immunohistochemistry in different parts of brain, testis and some other 
human tissues. The tissues listed in Table 2 showed positive staining with AZIN2 
antibodies.  
Table 2. Human tissues and cell types in which AZIN2 is expressed detected by 
immunohistochemistry, mRNA dot blot, or in situ hybridization.  
FUNCTIONAL ENTITY ORGAN 
Nervous system central and peripheral 
Reproductive organs testis, ovary, uterus 
Neuroendocrine tissues adrenal, intestine, neuroendocrine tumors, 
pancreas, parathyroid, pituitary 
Tissues secreting or 
storaging 




Immunohistochemical stainings from sections of human testis with the antibodies to 
AZIN2 revealed robust reactivity with the Leydig cells (III, Fig 1). A subtle granular 
positive signal was detected in spermatogonial cells. Occasional cells that represented 
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later stages of spermatogenesis, i.e. spermatocytes, also contained a few positively 
staining granules. Lopez-Contreras et al. (2008b) found a different distribution of 
AZIN2 in mouse testis. Their antibody to AZIN2 reacted mainly with haploid 
spermatids; they did not comment on the expression of AZIN2 in Leydig cells. Since 
Leydig cells were not visible in their micrographs, the estimate of the species-
dependent differences in the expression of AZIN2 is difficult to interpret. 
Furthermore, Lopez-Contreras et al. did not show any validation of their peptide 
antibody to mouse AZIN2. Interestingly, the interstitial Leydig cells in mouse testis 
have been found to express considerably higher ODC activity than the proliferating 
spermatogenic cells (Qian ZU et al. 1985) suggesting that it acts as an ODC inductor 
in these cells. 
 
Ovarian luteal cells produce steroid hormone similarly to the Leydig cells in testis. 
Immunohistochemical staining of sections from the ovaries of fertile women showed 
a strong expression of AZIN2 in luteal theca cells lining corpus luteum cysts (III, Fig 
2). No positive staining was seen in corpora albicantia or granulose cells of corpus 
luteum. Stainings of sections from postmenopausal ovaries revealed a strong 
positivity in the ovarian hilus cells which are responsible for progesterone synthesis.  
 
Intact ODC activity is needed for normal folliculogenesis and luteinization in mouse 
ovary (Bastida CM et al. 2005). Moreover, blocking of the preovulatory rise of ODC 
activity by in vivo treatment with DFMO abolished the secretion of progesterone by 
the corpus luteum (Bastida CM et al. 2002). Testosterone-producing Leydig cells of 
mature murine testis maintain high ODC activity (Qian ZU et al. 1985), whereas the 
ODC activity is lower in Sertoli and germ cells of adult rodents (Shubhada S et al. 
1989). Treatment with gonadotropins induces rapidly upregulated ODC activity in rat 
ovaries and testis (Osterman J et al. 1983, Maudsley DV et al. 1974). The 
gonodatropin-induced activation of ODC in gonads suggests that ODC has a role in 
the regulation of steroid hormone secretion or synthesis. ODC has a very short half-
life, and its de novo synthesis and release from an inactive complex with AZ is 
considered to occur in response to a stimulus, thus requiring the activity of AZIN. 
According to the results, AZIN2 could function as a part of a regulative machinery of 




In human and murine testis, a testis-specific AZ, AZ3, is expressed, and the 
preliminary hypothesis was that ODC, AZ3, and AZIN2 form a regulatory triangle in 
polyamine synthesis in testis.  The in situ hybridization studies of sections of normal 
human testicular tissue with an AZ3 probe nevertheless revealed a positive signal 
only in spermatids of the seminiferous tubules (III, Fig 3a) as previously shown in 
murine testis (Lopez-Contreras AJ et al. 2008b). Thus, no expression of AZ3 was 
detected in Leydig cells, showing that AZIN2 and AZ3 are mainly expressed in 
different cells of the human testis. Instead, expression of AZ1 has previously been 
reported to occur in both Leydig cells and Sertoli cells (Tosaka Y et al. 2000). López-
Contreras et al. (2008b) have reported co-expression of AZIN2 and AZ3 in haploid 
germ cells of mouse testis. As mentioned above, it remains to be clarified whether the 
seemingly discrepant findings reflect biological differences between human and 
mouse testis, or differences of antibodies to detect alternatively spliced forms of 
AZIN2. In conclusion, the interaction between AZ3 and AZIN2 in haploid germ cells 
still needs to be studied further. Since no expression of AZ3 in Leydig cells or 
alternative splicing has been detected, it is likely that AZ1, rather than AZ3, is a 
regulatory counterpart of AZIN2 in Leydig cells. 
 
Despite its high expression in Leydig cells and ovarian luteal cells, Sertoli cells in the 
normal seminiferous tubules remained unstained with antibodies to AZIN2.  This 
applied also to hyperplasic Sertoli cells in testis biopsies from patients with germ cell 
aplasia or Sertoli cell-only syndrome. These results indicate that AZIN2 is not a 
general marker for endocrine cells in the gonads. The expression of AZIN2 was  also 
investigated in testicular neoplasms derived from either Leydig cells or germinal 
epithelium, and in ovarian thecomas. All of the Leydig cell tumors studied (n=4) 
stained positively for AZIN2 (III, Fig 1g, h). In addition, a scattered granular staining 
of AZIN2 was seen in ovarian thecomas (III, Fig 2d). Instead, no staining for AZIN2 
was seen in neoplasms derived from the germinal epithelium (seminomas (n=5), yolk-
sac tumors (n=2), or embryonal carcinomas (n=3), data not shown). However, as far 
as can be quantified from immunohistochemistry, the expression level of AZIN2 was 
lower in the neoplastic than in normal Leydig cells. The expression of AZIN2 seems 
to be restricted to more mature and terminally differentiated cells. The same 
observation was made when comparing the levels of AZIN2 mRNA in the brain and 




Different parts of the human brain were studied immunohistochemically for the 
expression of AZIN2 with two peptide antibodies (IV, Table 1). The neuronal tracts 
were strongly visualized in all studied areas. Axon bundles emerging from lamina V–
VI were strongly positive in the neocortex and white matter (IV, Fig 1). Also 
dendrites in the subpial plexus were visualized. In the hippocampus, AZIN2 was 
detected in axons of the dentate gyrus, of the perforant pathway, alveus, and 
entorhinal cortex. In the cerebellum, the axons of basket cells and Purkinje cells 
expressed AZIN2. Also the tracts of the thalamus and medulla oblongata showed 
abundant reactivity. Staining of the temporal and frontal lobe visualized AZIN2 also 
in the soma of medium and large pyramidal neurons in lamina III–V. However, the 
expression of AZIN2 in the somas of pyramidal neurons differed between adjacent 
areas in the neocortex, giving an impression of spatial and/or temporal regulation of 
AZIN2 expression. This might implicate a selective expression of AZIN2 in cells with 
certain neurotransmitters, or as a response to neuronal activation. In situ hybridization 
further demonstrated the regional distribution of cells expressing AZIN2 mRNA. In 
addition to the neocortex, somas of some neurons in the medulla oblongata and 
Purkinje and basket cells in the cerebellum also expressed AZIN2. Neurons of the 
hippocampus, basal ganglia, and thalamus expressed only minor reactivity with 
antiserum 2. In the sections from the temporal lobe, AZIN2 was occasionally detected 
in the cytoplasm of oligodendrocytes. Kindling and other strong electrical stimuli 
evokes also expression of ODC in glial cells {{3 Bernstein,H.G. 1999; }}. In 
accordance with the expression pattern and cell type specificity of AZIN2 determined 
from testicular tissues, this protein functions only in terminally differentiated cells. 
Considering the variety of cellular functions in which ODC and polyamines 
participate, it seems likely that their inductors AZIN1 and AZIN2 not only are 
differently distributed but also replace each other in the regulation of different cellular 
phenomena. It is noteworthy that AZIN1 and AZIN2 are also expressed 
simultaneously in certain cell types, including neurons and Leydig cells. This fact 
further emphasizes the selectivity in their regulatory functions. The distribution in 
different subcellular compartments could provide a mechanistic way to elucidate the 




2.4. Subcellular distribution of AZIN2 
 
In order to understand the biological role of AZIN2, its intracellular localization is of 
fundamental importance. The current knowledge of the distribution of AZIN2 in 
subcellular compartments is derived from immunohistochemical stainings and cell 
fractionation studies.  
 
 
Figure 4. Antizyme (AZ), antizyme inhibitor 1 and 2 (AZIN1-2), ornithine 
decarboxylase (ODC), and polyamines (PA) are localized in various intracellular 
organels. 1. nucleolus, 2. nucleus, 3. ribosome, 4. vesicle, 5. rough endoplasmic 
reticulum, 6. Golgi apparatus, 7. cytoskeleton, 8. smooth endoplasmic reticulum, 9. 
mitochondrion, 10. vacuole, 11. cytosol, 12. lysosome, and 13. centriole. The original 
figure of the morphological cell was produced by Messer and Szczepan (Wikipedia, 
cc-by-sa).  
 
Immunohistochemical stainings invariably show a vesicular or granular distribution of 
AZIN2 in human cells. In the somas of neurons, these vesicle-like structures which 
contain AZIN2 were visualized in the soma close to the plasma membrane (IV, Fig 
3A). In axons, AZIN2 was also observed in granular or vesicle-like structures along 
the processes (IV, Fig 3B). As in the somal area, AZIN2 was localized close to the 
inside of the plasma membrane following the outer boundaries of the neurite. The 
vivid traffic of neurosecretory granules along the axonal cytoskeleton depends greatly 
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on the activation of small G proteins (for a review, see Ng EL et al. 2008). Given the 
present results on the regulation of cytoskeleton dynamics via the polyamination of a 
G protein RhoA (I), it is tempting to speculate that AZIN2 might regulate ODC-
dependent local polyamination of also other G proteins involved in the traffic of 
neurosecretory vesicles. 
 
A distinct granular distribution of AZIN2 was found in the lateral neurons of the 
medulla oblongata (area of spinal trigeminal and ambiguous nuclei) and the Purkinje 
cells of cerebellum. This staining was not restricted to the vicinity of the plasma 
membrane, but was rather dispersed throughout the cytoplasm and along the apical 
dendrite. A similar vesicular distribution of AZIN2 was detected in several types of 
endocrine and secreting cells (Fig 5), e.g. in the Leydig cells and spermatogonia of 
testis (III, Fig 1). The vesicular distribution of AZIN2 has also been clearly 
demonstrated in mast cells. The vesicle traffic of serotonin granules was linked to the 
distribution and expression of AZIN2 as well as to the catalytic activity of ODC 
(Kanerva K et al. 2009). 
 
Figure 5. The expression of antizyme 
inhibitor 2 in human sweat gland 
detected by immunohistochemistry. 
The glandular parts show high vesicle-
like expression whereas in ductal parts 
(indicated by arrowheads) the 
expression is low or absent. 
 
 
The association of AZIN2 with membranes was demonstrated from membrane 
fractions of cultured cells transfected with flag-tagged AZIN2 (Lopez-Contreras AJ, 
et al. 2006). No mitochondrial localization of AZIN2 could be detected by our 
doublefluorescent stainings with antibodies to AZIN2 and MitoTracker (Molecular 
Probes) (Kanerva K et al. 2008) even though this has been suggested earlier (Lopez-
Contreras AJ et al. 2006). When epitope-tagged AZIN2 localization was studied in 
more detail, AZIN2 localized to the ER-Golgi intermediate compartment and the cis-
Golgi network (Lopez-Contreras AJ et al. 2009). This further emphasizes  that AZIN2 
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is likely associated with vesicle trafficking. However, the subcellular localization of 
AZIN2 from transfected cells has to be interpreted with caution since overexpression 
due to efficient transfection might saturate the cellular compartments and contort the 
intracellular distribution. An additional epitope linked to a protein may also influence 
the subcellular distribution. 
 
There are only a few studies on the intracellular distribution of AZIN1. It is 
considered, however, to be diffusely distributed over the cytoplasm and is also found 
in the nucleus (Lopez-Contreras AJ et al. 2009). The nuclear localization fits with its 
function in the regulation of cell proliferation. Interestingly, we have occasionally 
observed nuclear staining of also AZIN2 in tissue specimens detected by 
immunofluorescence and immunohistochemistry and also more frequently in cultured 
cells transfected with AZIN2 (IV, Kanerva K et al. 2009, and our unpublished data).  
 
2.5. Functional implications of AZIN2 
 
AZIN2 has no known catalytic activity, and functions inside a cell in regulating the 
concentration of polyamines. Although less efficiently than AZIN1, AZIN2 binds the 
ODC inhibitor AZ and liberates ODC monomers, enabling the formation of 
catalytically active homodimers of ODC (Kanerva K et al. 2008, Snapir Z et al. 
2008a). In addition, AZIN2 increases the uptake of polyamines to the cell (Lopez-
Contreras AJ et al. 2008a). The amount of AZ is controlled independently of AZIN: 
the transcription is upregulated by high a polyamine concentration, and AZ is 
ubiquitinated to signal degradation (Gandre S et al. 2002). Nevertheless, AZIN1 and 2 
may function as local inductors of polyamine synthesis in selected subcellular 
compartments. 
 
AZIN1 is distributed ubiquitously, and its expression is stimulated by mitotic 
signaling (Nilsson J et al. 2000). It is also highly expressed in certain cancers, 
indicating a role in cell transformation and malignant growth (Jung MH et al. 2000, 
Schaner ME et al. 2005, Keren-Paz A et al. 2006). Instead, AZIN2 expression was 
low or absent in cancer cell lines (II, Fig 3) and it is less potent in stimulating growth 
(Snapir Z et al. 2008a). Our results show high expression of AZIN2 in terminally 
differentiated cells, including neurons, Leydig cells, luteal ovarian cells and mast 
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cells, implying that it is evidently not connected with cell proliferation. It thus appears 
that AZIN1 and AZIN2 regulate ODC for different purposes (III, IV, Kanerva K et al. 
2009).  
 
In the steroid-hormone-producing cells of testis and ovary, the activity of ODC is 
stimulated by luteinizing hormone (LH) (Osterman J et al. 1983, Maudsley DV et al. 
1974). Analogously, in the adrenal, where we have detected AZIN2 expression, 
adrenocorticotropin stimulates the activity of ODC (Levine JH et al. 1973). 
Furthermore, DFMO-mediated inhibition of LH-induced stimulation of ODC activity 
dramatically decreased the production of progesterone in mouse corpus luteum 
(Bastida CM et al. 2002). These observations indicate that polyamines and ODC have 
an important role in the regulation of steroid hormone synthesis and/or release. 
Evidence for a connection between the AZIN2-polyamine system and cellular 
secretion was also obtained from mast cells. These cells contain large granules which 
are released upon stimulation. The intracellular localization of AZIN2 to vesicle-like 
structures proceeded along with granule movement, and its expression was elevated 
also in degranulating mast cells (Kanerva K et al. 2009). Inhibition of ODC by 
DFMO prevented the release of serotonin granules. These findings suggest that 
AZIN2 has a functional role in mast cells in vesicle movement as a regulator of 
polyamines.   
 
Polyamines and ODC are related to the functional regulation of ion channels in the 
CNS. The inward rectifier K+ channels that regulate membrane potential and cell 
excitability are blocked by polyamines (Fakler B et al. 1994, Ficker E et al. 1994, 
Lopatin AN et al. 1994). Polyamines also inhibit the AMPA- and kainate-dependent 
fast depolarization of glutaminergic synapses, and thereby modulate neurotransmitter 
signals (Kamboj SK et al. 1995, Bowie D et al. 1995). The N-methyl D-aspartate type 
excitatory glutamate receptors (NMDAR) form glutamate-gated ion channels in the 
brain and mediate synaptic plasticity which is pivotal for cognitive functions, such as 
memory and learning (Bliss TV et al. 1993). NMDARs are regulated by polyamines 
in multiple ways: the binding of polyamines from the extra- or intracellular side to 
NMDAR can either enhance or inhibit the influx of Ca2+ (Araneda RC, et al. 1999, 
Benveniste M et al. 1993, Durand GM et al. 1993). Pretreatment of cultured mouse 
cortical neurons with DFMO abolished NMDA-induced neurotoxicity (Markwell MA 
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et al. 1990). This indicates that intracellular levels of polyamines are involved in the 
functioning of NMDAR. Since AZIN2 regulates polyamines, double 
immunofluorescence was used to investigate the interrelationship between AZIN2 and 
NMDAR. All the cells expressing AZIN2 were also positive for NMDAR1, even 
though NMDAR1 was more widely distributed, and AZIN2 showed a more restricted 
pattern of expression. This demonstrates overlapping localization of AZIN2 and 
NMDAR1 in the cytoplasm of large pyramidal cells in the neocortex of normal brain 
(IV, Fig 4). Although the molecular details are largely unknown, the local regulation 
of the ODC activity and the concentration of polyamines are obviously important for 
the functioning of the channels and for neurotransmitter signalling. In biochemical 
assays, AZIN2 not only stimulates the intracellular polyamine synthesis, but also 
regulates the local extracellular concentration by enhancing the uptake of polyamines 
(Kanerva K et al. 2008, Lopez-Contreras AJ et al. 2008a). NMDARs circulate 
constantly between the synaptic plasma membrane and cytoplasmic vesicles upon 
neuronal activation and sensory experience, thereby contributing to long-term 
potentiation (Grosshans DR et al. 2002, Quinlan EM et al. 1999). Vesicles containing 
NMDAR are transported along microtubules to the postsynaptic density and 
extrasynaptic areas (Washbourne P et al. 2002, Tovar KR et al. 1999). Given that 
polyamines regulate NMDAR, AZIN2 might influence glutamate-mediated signalling 
by controlling the local synthesis of polyamines.  
 
Most of the ODC in the brain is bound to antizyme which blocks its enzymatic 
activity (Laitinen PH et al. 1986, Laitinen PH 1985, Laitinen PH et al. 1985). 
However, various stimuli, including electrical and chemical stimulation, and 
traumatic injuries, activate ODC (Pajunen AE et al. 1978, Bondy SC et al. 1987, 
Martinez E et al. 1991, Baskaya MK et al. 1996, Dienel GA et al. 1984). Elevated 
ODC activity and concentration of putrescine have been detected in the brain in 
pathological conditions such as ischemia and Alzheimer’s disease (AD) (Lukkarinen 
JA et al. 1999, Keinänen R et al. 1997, Bernstein HG et al. 1995, Morrison LD et al. 
1995, Morrison LD et al. 1998, Paschen W et al. 1991). In AD, the pathological 
accumulation of β-amyloid induces activation of ODC, in addition to its ability to 
provoke the generation of neurotoxic reactive oxygen species (Nilsson T et al. 2006b, 
Behl C et al. 1994, Hensley K et al. 1994). Putrescine functions as a scavenger of free 
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radicals and thereby buffers the cytotoxic effects of ROS (Yatin SM et al. 2001). 
Yatin et al. have further shown that β-amyloid, in addition to inducing ODC activity, 
also stimulates polyamine uptake (Yatin SM et al. 1999). The cellular uptake of 
polyamines and the induction of ODC activity are regulated by AZINs. The 
expression of AZIN2 in 15 human brains affected by AD was studied in sections from 
the frontal lobe and the hippocampus (IV, Fig 5). The regional variation of AZIN2 
expression seen in normal brain was abolished and, instead, virtually all the pyramidal 
cells in the frontal cortex stained positively for AZIN2. The individual cells of the AD 
brains also appeared to contain larger amounts of AZIN2. In the pyramidal cells, 
AZIN2 was seen in large aggregates or in vacuoles. The hippocampal regions CA1-3 
of AD brains displayed a robust expression of AZIN2 that was not found in samples 
of normal brain. In the axons, which appeared swollen, AZIN2 was accumulated in 
vacuole-like aggregates that were larger than those seen in the axons of normal brain 
tissue. The subcellular localization of ODC has also been reported to be influenced by 
AD. Nilsson et al. found evidence for translocation of ODC from the nucleus to the 
cytoplasm of neocortical pyramidal cells in the early phase of AD. In addition, 
elevated expression of ODC was found in Purkinje cells of the cerebellum and in the 
hippocampus of AD brains (Nilsson T et al. 2006a). Elevated expression of AZIN2 
was also detected in Purkinje cells and the hippocampus in AD. However, earlier 
reports on the immunohistochemical location of ODC have to be considered with 
caution since the antibodies used were raised before the identification of AZIN2. 
They may therefore have caused substantial cross-reactivity due to the high degree of 
structural homology between ODC and AZIN2. The accumulation of AZIN2 in AD 
may nevertheless provide neuroprotection by enhancing the production and uptake of 
putrescine stimulated by β-amyloid. 
 
The expression of AZIN2 in the brain was not increased in the other 
neurodegenerative diseases studied. In the samples from patients with CADASIL 
dementia and from patients with dementia with Lewy bodies (DLB), the expression of 
AZIN2 was similar to that seen in samples from the corresponding areas of normal 
brain. The neuronal accumulation of AZIN2 is therefore merely a feature of AD. 
Polyamines, and in particular spermine, have been associated with the pathogenesis of 
Lewy body dementia and Parkinson’s disease. The binding of spermine to α-
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synuclein provokes its folding and leads to the formation of aggregates (Grabenauer 
M et al. 2008). The aggregation of α-synuclein is considered to be a major 
pathological event in these neurodegenerative diseases. It would be of interest to 
study whether yet uncharacterized splicing variants of AZIN2 are related to 




CONCLUSIONS AND FUTURE PERSPECTIVES 
 
 
A novel molecular mechanism was introduced by which ODC and polyamines 
regulate the reorganization of actin cytoskeleton.  The small G protein RhoA is 
polyaminated by transglutaminase, leading to its activation. Activated RhoA induces 
changes in cytoskeletal dynamics. Polyamination of RhoA occurs physiologically 
during mitosis, and explains why polyamines are needed for the cell cycle to the 
progress from mitosis to G1. During cytokinesis, active RhoA is known to accumulate 
in cleavage furrow and to regulate the contractile actin-myosin fibers in the mitotic 
spindle.  
 
Polyamine synthesis is not the only way by which ODC controls the functioning of 
RhoA. The membrane translocation of ODC, which is crucial for its transforming 
capacity, either directs RhoA to the vicinity of the plasma membrane, or is needed for 
the local maintenance of active RhoA. It is of importance since RhoA is active in the 
membrane and inactive in the cytoplasm. 
 
Constitutive overexpression of ODC leads to the transformation of NIH 3T3 cells, and 
high activity of ODC has been observed in many cancers. Cytoskeletal 
rearrangements are a major event in proliferation, attachment, and migration of cells. 
Thus, they play a crucial role in transformation and the behaviour of malignant cells. 
The results provide a mechanistic link between polyamines and the actin 
cytoskeleton, and help in understanding how polyamines influence cell 
transformation. In the future, it would be interesting to evaluate the polyamination 
status of RhoA in different types of malignant cells and to test the tumor promotion 
and metastasizing capacity of cells in which the polyamination of RhoA is 
manipulated. 
 
A new member has been characterized in the polyamine-regulative family in addition 
to ODC and AZIN1. This novel protein was devoid of ODC activity and was termed 
as AZIN2. The expression of AZIN2 was mainly found in terminally differentiated 
cells including neurons and Leydig cells. This suggests that the  role of AZIN2 differs 
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from that of AZIN1, which is implicated in the regulation of growth and proliferation. 
Another distinction from AZIN1 is the extensive alternative splicing of AZIN2 
transcripts. It appears evident that there is selective expression of variants between 
cell types and even subcellular compartments. However, the ultimate biological 
significance of these remains to be determined. 
 
Immunohistochemical stainings of sections from different human tissues appoint to 
their correlation with vesicle function. The high expression of AZIN2 in testosterone-
producing Leydig cells and progesterone-secreting luteal cells of male and female 
gonads, respectively, suggest an association with secretion and vesicle function. 
Future aims will be focussed more closely on the vesicles to which AZIN2  localizes, 
and the role of AZIN2 in vesicle function will be investigated. 
 
In brain, polyamines regulate NMDA-type glutamate receptors responsible for 
excitatory signalling, as well as Kir channels which monitor the threshold for action 
potentials. As AZIN2 colocalizes with NMDAR1 in human brain, it would be of 
interest to study whether AZIN2 serves as a local inductor of polyamine synthesis in 
the vicinity of glutamate receptors and in this way regulates their function. An 
accumulation of AZIN2 in neurons was detected in AD. Whether it is a consequence 
of pathological changes in neurons or a part of pathogenesis itself remains to be 
clarified. However, this result emphasizes the importance of studying further the role 
of polyamines and ODC in AD. However, the accumulation of AZIN2 is not a general 
response to neurodegeneration, since no accumulation was detected in neurons from 
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